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Abstract 
 
 
 
 
 
 
 
 
 
 
 ABSTRACT 
Introduction: The use of adult stem cells in cell-mediated therapies is an area of 
considerable interest within tissue regeneration research. However, important 
variables such as the distribution of the injected cells, cell survival, target organ 
localisation cell proliferation and differentiation cannot be evaluated in vivo by using 
classical imaging approaches. This study propose multiple labelling protocols for in 
vivo visualisation by MRI, nuclear imaging and BLI of adult murine neural stem cell-
mediated therapy, in spinal cord injury animal models. 
Methods: Murine neural stem cells (mNSCs) were directly labelled with different 
amounts of SPIOs (0 - 100 - 200 - 400 µg Fe/ml) in the culture medium and 
incubated with iron labelled medium for 24, 48 or 72 h in presence of carriers such as 
poly-L-Lysine (PLL), polybrene (PB) and protamine sulphate (PS). PLL and PS were 
tested at different ratio (Fe/PLL 1:0,03, 1:0,06 and 1:0,09 and Fe/PS 1:0,025 and 
1:0,05). Labelled cells were analysed for viability, iron content (Perl’s Staining and 
spectrophotometer analysis), morphology, staminality and differentiation capability. 
After the labelling protocol set up, the loaded cells were injected into the tail vein of a 
spinal cord injury murine model and their distribution was followed by MRI for two 
months. Initial cell distribution was also followed by nuclear imaging after cell 
labelling with 111In-oxine (60 µCi/106 cells). Cells localization, distribution e viability, 
over time, were analysed in vivo by BLI after injection of mNCS infected with a viral 
vector expressing Luciferase under a PGK constitutive promoter (PLW vector). 
Results: the iron content/cell increased in proportion to the incubation time and to 
the iron concentration in the medium and in relation to different carriers (PLL, PB and 
PS) in labelled mNSCs. Longer incubation time (48 and 72h) and higher iron 
concentration (400 µg Fe/ml) resulted in marked toxicity and lower cell viability. The 
use of PB and PLL, as carriers, didn’t produce any increase of the labelling 
efficiency. The incubation for 24h with 200 µg Fe/ml in presence of different amount 
of PS didn’t influence significantly the cell viability and the proliferation rate. 
Furthermore, the percentage of iron-positive cells and the iron content/cell increased 
in proportion to the PS content in the medium even if higher amount of PS (Fe/PS 
1:0.05 ratio) resulted in an aberrant morphology. For this reason, 200 µg Fe/ml 
incubated with Fe/PS 1:0.025 ratio for 24h, has been chosen as the best labelling 
condition. 
Labelled cells were able to form new neurospheres and maintained the nestin 
expression demonstrating the maintenance of self-renewal capability and stem cell 
features and were also able to differentiate, as confirmed by β-tubulin III and GFAP 
expression analysis.  
Nuclear imaging confirmed initial distribution to filter organs while MRI allowed to 
detect the presence of an iron signal due to stem cell localization into the lesion site 
since 7 days after injection. BLI permitted to demonstrate the viability of PLW 
infected mNSCs migrated at the lesion site and supported the MRI data.  
Conclusions: These results permitted to conclude that NSCs can be efficiently 
labelled with different molecules without significantly perturbing physiological stem 
cell features and self-renewal capability. These labelling protocols can be applied for 
the in vivo visualisation by MRI, nuclear imaging, and BLI of the distribution of stem 
cells after their transplantation into murine model of disease. 
 
 RIASSUNTO 
Introduzione: L’utilizzo delle cellule staminali adulte nella terapia cellulo-mediata è 
di grande interesse nella ricerca sul trattamento e la ricostituzione dei tessuti 
danneggiati da traumi e malattie degenerative ed infiammatorie. 
Tuttavia, importanti variabili come la distribuzione delle cellule iniettate, la 
sopravvivenza cellulare, la localizzazione all’organo target, la proliferazione ed il 
differenziamento cellulare non possono essere valutate in vivo. Lo scopo di questo 
studio è quello di mettere a punto diversi protocolli di marcatura per la 
visualizzazione in vivo, tramite MRI, imaging nucleare e BLI, di cellule staminali 
neurali murine adulte (mNSCs) utilizzate nel trattamento del trauma spinale in 
modelli animali. 
Metodi: Le mNSCs sono state marcate in modo diretto con differenti concentrazioni 
di SPIOs (0 - 100 - 200 - 400 µg Fe/ml) nel terreno di coltura e incubate con il terreno 
marcato per 24, 48 e 72 ore in presenza di agenti trasfettanti come poli-L-Lisina 
(PLL), polibrene (PB) e protamina solfato (PS). PLL e PS sono state testate a 
differenti rapporti (Fe/PLL 1:0,03, 1:0,06 e 1:0,09 e Fe/PS 1:0,025 e 1:0,05). Le 
cellule marcate sono state analizzate per quanto riguarda la vitalità cellulare, il 
contenuto di ferro (colorazione di Perl e analisi spettrofotometrica), la morfologia ed il 
mantenimento della staminalità e delle capacità differenziative. Dopo la messa a 
punto dei protocolli di marcatura, le cellule marcate sono state iniettate nella vena 
caudale di un modello murino di trauma spinale e la loro distribuzione è stata seguita 
per due mesi tramite MRI. La distribuzione iniziale delle cellule è stata anche seguita 
tramite scintigrafia dopo la marcatura cellulare con 111In-oxina (60 µCi/106 cellule). La 
localizzazione, la distribuzione e la vitalità cellulare nel tempo sono state analizzate 
in vivo anche tramite BLI dopo il trapianto delle mNSCs infettate con un vettore 
lentivirale esprimente il gene Luciferasi sono il controllo del promotore costitutivo 
PGK (vettore PLW). 
Risultati: L’accumulo intracellulare di Ferro nelle mNSCs è risultato proporzionale al 
tempo di incubazione e alla concentrazione di ferro nel terreno di coltura e ai 
differenti agenti trasfettanti (PLL, PB e PS). 
Al contrario, tempi di incubazione più lunghi (48 e 72 ore) e concentrazioni maggiori 
di ferro (400 µg Fe/ml) hanno determinato un evidente aumento della tossicità e in 
una minore vitalità. L’utilizzo di PB e PLL non ha prodotto aumenti statisticamente 
significativi del contenuto di ferro intracellulare. 
L’incubazione per 24 ore con 200 µg Fe/ml marcate, in presenza di differenti 
concentrazioni di PS, non ha influenzato in modo significativo né la vitalità né la                    
capacità proliferativa delle cellule. Inoltre, la percentuale di cellule ferro-positive è 
aumentata in proporzione al contenuto di PS nel terreno di coltura anche se alte 
concentrazioni di PS (ratio Fe/PS pari a 1:0.05) hanno avuto come conseguenza una 
morfologia aberrante. Per questo motivo 200 µg Fe/ml in presenza di PS (1:0.025 
Fe/PS) per 24 ore di incubazione è risultata essere la migliore condizione di 
marcatura.  
Come dimostrato dal mantenimento dell’espressione della nestina e della capacità di 
dare origine a nuove neurosfere, la marcatura non ha condizionato né la staminalità 
e né la capacità di autorinnovamento. Inoltre la marcatura non ha influenzato la 
capacità differenziativa delle mNSCs come confermato dall’analisi dell’espressione 
della β-tubulina III e della GFAP. Questi dati hanno permesso di dimostrare che le 
  
condizioni di marcatura cellulare non influenzano le caratteristiche fenotipiche e 
funzionali delle cellule staminali.  
L’ imaging nucleare ha confermato la distribuzione iniziale agli organi filtro mentre 
l’MRI ha permesso di rilevare la presenza delle cellule marcate con il ferro nel sito di 
iniezione sin dal settimo giorno dopo la somministrazione. 
Il BLI ha permesso di dimostrare la vitalità delle mNSCs infettate con PLW migrate al 
sito di lesione ed ha confermato i dati di MRI. 
Conclusioni: Questi risultati hanno permesso di dimostrare che le mNSCs possono 
essere efficientemente marcate con molecole differenti senza perturbare in modo 
significativo la loro fisiologia e morfologia cellulare e la capacità di auto-
rinnovamento. Questi protocolli di marcatura possono essere applicati per la 
visualizzazione in vivo tramite MRI, imaging nucleare e BLI, della distribuzione delle 
cellule staminali dopo il trapianto nel modello murino lesionato. 
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1. SPINAL CORD INJURY 
A spinal cord injury (SCI) is a damage or trauma to the spinal cord that results in a 
loss or impaired function causing reduced mobility or feeling in the regions 
downstream the lesion. Common causes of damage are traumas (car accident, 
gunshot, falls, sports injury, etc.) or diseases (Transverse mieliti, Polio, Spina 
Bifida, Friedreich’s atassia, etc.).  
In SCI, the traumatic destruction of nerve fibres that carry motor signals from the 
cortex to the torso and limbs leads to muscle paralysis. In addition, destruction of 
nerve fibres can lead to loss of sensation, such as touch, pressure and 
temperature. 
The traumatic spinal cord injury (TSCI) affects many people (15-40 cases every 
million people), most often of young age; the prospects of recovery are very small 
and the disability is permanent. The emotional and economic costs of spinal cord 
injury are great, especially for the long-term nursing care needed by serious 
disability. Despite multiple therapeutic approaches that target different aspects of 
the pathophysiologic cascade contributing to SCI, there have been no significant 
advances in clinical care that reliably attenuate injury or restore function. 
From a pathophysiological perspective, SCI has been divided into two distinct 
phases [1]. 
Primary injury is an immediate response resulting from the direct action of 
mechanical force on the spinal cord. The strong inflammation initiated as a 
response to primary injury successively causes tissue edema, extensive 
demyelination, and cell death [2]. Secondary injury consists of all pathological 
events initiated by the original mechanical insult. The secondary injury following 
SCI is the result of a stroke-like ischemic insult; the biochemical and metabolic 
events associated to the vascular disregulation are numerous, and lead to the 
progressive degeneration that may exceed the early mechanical damage. 
The pathophysiology of the spinal cord after the injury is mediated by a complex 
interplay of pro-inflammatory molecules and cytokines (MIP-2, TNFα, IL-1β, and IL-
6), anti-inflammatory molecules and migratory cells. 
Within the first 12 h, neutrophils first appear. MIP-2 overproduction associated to 
neutrophil infiltration suggests that this mediator plays a key role in inflammatory 
cell recruitment induced by SCI [3][4]. Within the 24-48h also lymphocytes and 
microglia mobilize to the injury site. Primary and secondary degeneration events 
together determine the extent of tissue damage even much farther than the limits of 
the mechanical impact. The attenuation of cellular and molecular abnormalities 
derived from the secondary injury may improve the recovery from SCI-derived 
disability. 
Some pharmacological treatments, have, as goals, the attenuation of secondary 
ischemia-derived degeneration responsible for the worsening of initial conditions 
and the prevention of the neutrophilic and macrophagical infiltration into the site of 
injury [5]. 
1.1. Spinal cord injury therapy 
Although, recently, the progresses in the field of spinal cord injury treatment have 
significantly improved the conditions and life expectancy of patients, nowadays 
 3 
 
 there are no real solutions for the recovery from a spinal cord injury. The surgical 
intervention aims to stabilize the spine in case of instability, cancels the risk of 
further spinal cord damage going to remove bone fragments and eventual discs 
occupying the spine canal and compressing it to maximize the chances of 
functional recovery of spinal affected by trauma.  
However, recently, research has achieved encouraging results regarding the 
modulation of the inflammatory process but failed to induce regeneration of 
neurons lost with the trauma. 
A decade ago, researchers demonstrated a small but significant neuroprotective 
and anti-inflammatory effect from an adrenal corticosteroid drug 
(methylprednisolone). It is the only treatment currently available to limit the extent 
of spinal cord injury and its risks are relatively low. Several studies continue to 
search for additional anti-inflammatory treatments that might prove even more 
effective. 
Preliminary clinical trials of another compound, GM-1 ganglioside, indicate that it 
could be useful in preventing secondary damage in acute spinal cord injury. A large 
randomized clinical trial, suggested that it might also improve neurological recovery 
from spinal cord injury during rehabilitation.  
These observations and others, have led to optimism that recovery can be 
improved by altering cellular responses immediately after injury. 
Additional neuroprotective therapies, to prevent the spread of post-injury damage 
and preserve surrounding tissue, have been studied and tested thanks to the 
acquired knowledge about the mechanisms that cause secondary damage, such 
as excitotoxicity, inflammation and apoptosis.  
 
The goals of research studies in the spinal cord injury treatment are the following: 
• Stopping excitotoxicity  
When neurons die, they release excessive amounts of glutamate which floods 
the cellular environment and pushes cells into apoptosis. Several studies are 
investigating compounds that could keep nerve cells from responding to 
glutamate, potentially minimizing the extent of secondary damage. 
• Controlling inflammation 
Within the first 12 hours after injury, the first wave of immune cells infiltrates 
the damaged spinal cord to protect it from infection and eliminate dead 
neuronal cells. The immune cells act and release cytokines, the hallmark of 
inflammation. 
Although cytokines can be toxic to neuronal cells because they stimulate the 
production of free radicals, nitric oxide, and other inflammatory substances that 
cause cell death, they also stimulate the production of neurotrophic factors, 
which are beneficial to cell repair. 
The aim of the research, currently, is to control the immune system cells and 
correlated molecules by encouraging their potential for neuroprotection and 
reducing their neurotoxic effects.  
• Preventing apoptosis 
Several days after the initial injury, apoptosis spreads in damaged and nearby 
tissue. The exact biochemical events regulating apoptosis are not yet 
completely known. 
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Further studies are aimed at understanding these cellular mechanisms more 
fully. These studies will provide an opportunity to develop neural protective 
strategies to combat apoptotic cell death. 
• Stimulating regrowth of axons 
Stimulating the regeneration of axons is a key component of spinal cord repair. 
The reconnection of axons injured during the spinal cord trauma could increase 
the chances for recovery of function. 
However, to get the axons growth after injury is a complicated matter. Central 
nervous system (CNS) neurons have the capacity to regenerate, but the 
environment in the adult spinal cord does not encourage growth. In adult CNS 
lacks all the cytokines and growth factors responsible of the early development 
of CNS and it also contains molecules that actively inhibit axon extension. For 
a successful transplant the environment has to be changed. 
At the present time, several studies are focusing their attention on neurotrophic 
factors and guidance molecules such as ephrins, semaphorins and netrins.  
During the development of CNS, in fact, axons grow following the axonal 
growth cone, an active tip only a few thousandths of a millimeter in diameter, 
which interacts with chemical signals that stimulate growth and direct 
movement.  
In the adult CNS, the myelin, which contains growth-inhibiting proteins, creates 
an hostile environment to axon growth. 
These proteins appear to preserve neural circuits in the healthy spinal cord and 
keep intact axons from growing inappropriately but in injured spinal cord, 
prevent regeneration. 
At least three growth-inhibitory proteins operating within the axonal tract have 
been identified: Myelin-associated glycoprotein (MAG), Nogo and 
oligodendrocyte myelin glycoprotein (OMgp). They are expressed by 
oligodendrocytes and bind to Nogo receptor (NgR) on neurons. These 
interactions result in inhibition of neurite outgrowth. The aim of research is to 
understand how these inhibitory proteins act, and then discover ways to 
remove or block them, or change how the growth cone responds to them. 
Axonal growth and neuronal cell survival are promoted by some regulatory 
proteins called Neurotrophic factors (or neurotrophins) which, however, in the 
injured spinal cord are downregulated instead of increased. Several studies 
have tested infusion pumps and gene therapy techniques to rise their levels 
post-injury and enhance regeneration.  
Once growth, the axons have to re-establish functioning synapses. Guidance 
molecules, proteins present on the surface of neurons and glia or secreted by 
these cells, act as chemical road signs, guiding axons growth in some 
directions rather than others. 
The supply of guidance molecules might encourage regeneration. The 
combination of these strategies could encourage growth, clear away debris, 
and target axon connections becoming a powerful treatment for spinal cord 
injury.  
• Promoting regeneration  
The new frontier in treatment of spinal cord trauma is represented by cell 
transplantation. Cell grafts transplanted into the injured spinal cord act as 
bridges across injured areas to reconnect cut axons. Several fetal spinal cord  
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(fSC) transplantation experiments, performed in animal models of TSCI, 
permitted to demonstrate that fSC grafts grew well in the host spinal cord, fill 
the cavity and fuse with the host spinal cord [6] creating a bridge that would 
span the injured area [7][8][9]. Fetal spinal cord tissue implants give rise to new 
neurons, which, when stimulated by growth-promoting factors (neurotrophins), 
extend axons in the spinal cord producing also an encouraging functional 
outcomes. Indeed the transplants improved locomotor recovery and were able 
to modulate the excitability of lumbar motor neurons [10][11][12]. The 
promoting action of fSC transplants was preserved if the time interval between 
injury and grafting did not exceed 3–4 months [13]. 
Recently, the attention is focusing on stem cells and in particular in neural stem 
cells. Stem cells are capable of dividing and yielding almost all the cell types of 
the body, including those of the spinal cord. They have a big potential even if 
their biology is not yet completely understood such as the function of different 
kind of chemical signals emitted by the cells and used for cell-cell 
communication. Some of these signals will have to be recreated in the region 
of the transplant  to stimulate proper growth and differentiation.  
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2. CELL- MEDIATED THERAPY 
The Food and Drug Administration (FDA) provides the following definition of cell 
therapy: “The prevention, treatment, cure or mitigation of diseases or injuries in 
humans by the administration of autologous, allogeneic or xenogeneic cells that 
have been manipulated or altered ex vivo” [14].  
The cell-mediated treatments, can be mainly divided into two classes: 
Immunotherapy, based on the administration of immune cells previously activated 
ex vivo and regenerative therapy based on the use of stem cells. 
The goal of stem cell mediated treatments, within the regenerative medicine, is 
repairing, replacing or restoring damaged tissues or organs (figure 1).  
There are different forms of cell therapy: 
• stem cells transplantation;  
• transplantation of mature and functional cells; 
• transplantation of modified cells used to produce a needed substances; 
• transplantation of cells extracted from a patient with a genetic aberration and 
opportunely modified to correct the genetic defect. 
• transplantation of trans-differentiated cells derived from the patient's own 
differentiated cells (for example insulin producing beta cells transdifferentiated 
from isolated hepatocytes as a treatment for diabetes). 
 
 
 
 
Figure 1: Procedures for cell therapy: A) precursor of stem cells are harvested 
from  
the patient itself or from a donor; B) in vitro selection or analysis, C) in vitro 
expansion, D) large in vitro expansion, E) administration to patient, F) monitoring of 
homing/migration, differentiation, surviving,  
effect of cell-therapy. 
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For what concerns stem cell therapy, bone marrow transplants have been used for 
the past 40 years to regenerate the blood and immune systems of patients with 
leukemia, lymphoma, severe aplastic anemia or inherited metabolic diseases. 
Unfortunately, the major limitation of allogeneic bone marrow transplants is the 
availability of matched donors.  
Stem cells from Umbilical Cord Blood (UCB) have emerged as an alternative to 
bone marrow transplants, providing an easily obtainable and readily available cell 
source for treatment. Until recently, UCB transplants were limited to paediatric 
patients due to the low amount of stem cells obtained. However, in 2004 was 
demonstrated that the combination of stem cells from two UCB units could increase 
the cell dose, making it possible to extend this lifesaving haematopoietic treatment 
to adult patients. 
 
Several studies have demonstrated that, in addition to regenerating the blood and 
immune systems, stem cells would also be used to replace damaged or diseased 
tissues and organs (cells for skin, muscle, liver, pancreatic islet cells, spinal cord 
injury, neurons).  
An example of cell mediated therapy consists of the use of stem cells for 
regenerative treatments in degenerative and inflammatory diseases or traumatic 
injuries. Many cell types have been used depending on the tissue to be treated: 
neural stem cells, muscle stem cells, bone marrow cells, or not yet committed cells 
have been used to induce transdifferentiation for different applications. 
Harnessing stem cells for using them as drug delivery systems is another goal for 
research; in fact stem cells may be able to bring chemotherapeutic agents directly 
to the target cancerous cells. They can also be used for the generation of liver cells 
or other tissues in order to screen new drug candidates for a safer pharmaceutical 
drug development process. The use of human cells or tissues may provide a better 
toxicology testing model than the traditional animal models currently in use. 
Stem cell-mediated therapies finds different applications also in the treatment of 
inflammatory disease such as inflammatory myopathies, degenerative disease 
(Parkinson’s, Alzheimer’s, Multiple Sclerosis, Huntington, ALS, etc.) and in the 
treatment of traumatic injuries, such as spinal cord injury. In this scenario, a cell-
mediated therapy could be useful in restoring the damaged tissue. 
One of the most promising field of study regards the use of neural stem cells 
(NSCs) and their application in the regenerative medicine. The therapeutic 
perspectives related to the use of NSCs are based on two important properties: 
their ability to proliferate indefinitely and their plasticity. In all situations in which 
neuronal loss occurs, the NSCs, previously isolated and expanded in vitro can 
restore the lost functions when implanted into damaged tissue or administered by 
intravenous injection. These cells can be directly transplanted or manipulated in 
vitro inducing their differentiation toward the neuronal phenotype of interest before 
infusion. 
Until now, several animal models of neurodegenerative diseases have been 
treated and at least partially cured by NSCs administration [15][16][17][18].  
Recently, during the course of the trials, new and unexpected properties 
associated with these cells have emerged. 
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The NSCs, injected intravenously or directly into the damaged tissue in animal 
models of neurological diseases, are able to migrate to tumour cells in brain 
tumours, some of which are resistant to chemotherapy and radiation. 
Starting from these findings, researchers over the years have engineered stem 
cells and neural precursors from adult or embryonic brain samples, and these cells 
have been used in studies of gene delivery to target genes or cytotoxic molecules 
in areas of interest. Unexpectedly, the same not manipulated NSCs, was 
demonstrated having cytotoxic properties against cancer cells in brain tumours. 
The mechanisms governing the tropism of NSCs in a specific way are not yet 
understood. 
The first intuitions are based on prior knowledge of the molecular mechanisms that 
regulate cell migration during inflammatory processes. It has been observed that 
ischemia induces upregulation of chemokine SDF-1a (stromal cell-derived factor), 
whose receptor CXCR4 (CX-C motif receptor 4) is expressed on NSCs; blocking 
CXCR4, NSCs migration is substantially reduced [19]. 
Moreover, the NSCs tropism for injuries is a very important feature for the 
treatment of multifocal diseases such as multiple sclerosis or inherited metabolic 
diseases affecting the CNS such as phenylketonuria, mucopolysaccharidosis, 
Niemann-Pick disease, Fabry disease, Tay-Sachs and Gaucher disease. In these 
cases, the treatment of multiple damaged areas can be performed by a single 
injection of NSCs or NSCs lines, as demonstrated by Snyders’ pioneering 
experiments in 1995 [20][21][22]. 
The NSCs ability to migrate toward the sides of injury in the adult brain has been 
confirmed in many experimental animal models of human diseases such as stroke, 
multiple sclerosis and experimental autoimmune encephalitis (EAE) [23][24]. 
Multiple sclerosis and EAE are demyelinating immune diseases that affects the 
CNS.  
From these animal models observation emerged that the undifferentiated NSCs 
could also have important regenerative properties, on the contrary to what was 
believed until then. The EAE animal models showed a visible recovery, although 
most of the infused NSCs do not differentiate into oligodendrocytes. It seems that 
these cells will make their therapeutic action, not replacing the damaged 
oligodendrocytes, but acting as suppressors of cerebral autoimmunity [25]. 
Another phenomenon associated with NSCs, common to other stem cells of adult 
tissue, is the transdifferentiation, a cellular adaptation in response to stimuli of 
growth: a reprogramming process by which a stem cell of a specific adult tissue, 
comes to generate a particular cell of another tissue. It has been shownthat cells 
derived from mouse bone marrow infused into the blood circulation are able to 
reach the brain and differentiate into neural cells [26]. 
As in rodents, also human hematopoietic stem cells can cross the blood-brain 
barrier, reach the brain and differentiate into neural cells. In post-mortem autopsy 
samples of female patients who underwent bone marrow transplantation from male 
donors were found neurons of hematopoietic origin identified by the presence of Y 
chromosome [27]. At the same time, murine NSCs are capable of generating blood 
cells [28]. It remains to determine whether, in some cases, transdifferentiation may 
be due to cell fusion [29][30]. 
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Regardless of the disease treated with a cellular therapy, the conception of the 
therapeutic products may require several complex procedures aimed at obtaining 
and/or modifying the cells. The steps may include: 
• Cell Harvesting 
• Cell Propagation  
• Cell Expansion  
• Cell Selection  
• Pharmacological treatment of cells  
• Alteration of the biological characteristics of cells 
  
Before the clinical application of cell-mediated therapies, the research should 
overcome several technical obstacles. 
The new goals for stem cell research should be:  
• To understand and control the mechanism of turning undifferentiated cells into 
specialized cells. This will involve the identification of the complex signals 
needed to turn on and off the cell differentiation process.  
• To identify, isolate and purify adult stem cell for safe and effective treatments.  
• To control the differentiation of stem cells into the cell types needed to treat 
disease, in order to make it possible the generation of the sufficient quantity of 
correct stem cells or differentiated cells suitable for the treatment. 
• To learn how to make patient-compatible the stem cell transplants, to avoid 
any rejection by the immune system.  
• To demonstrate the clinical improvement and normal cell development and 
function after stem cells have been transplanted or administered into the 
patient’s body. Cells have to integrate with patient’s own tissues and function 
as patient’s natural body cells. 
 
To overcome these problems, molecular and cellular imaging techniques could 
provide information about the homing, viability and differentiation of stem cells once 
injected during the therapy permitting an early evaluation of cell-mediated 
treatment efficacy potential. 
Specific cell populations can indeed be labelled and visualised in vivo through 
widely used methods such as magnetic resonance imaging, emission tomography 
and, only for animal models, bioluminescence and fluorescence imaging (see next 
paragraph). 
Through cellular imaging we may achieve an in-depth understanding of the 
fundamental aspects stem cell therapy in order to refine the therapeutic strategies 
for humans. In the protocols based on the use of stem cells, in vivo imaging can 
provide new methods for studying in vivo stem cell homing and their differentiation 
into the tissue of interest, as well as the value of the possible use of adjuvant 
pharmacological treatments over time. 
2.1. Cell therapies in the spinal cord injury 
One of the most promising field of application of regenerative medicine is the 
traumatic spinal cord injury treatment.  
Several types of cells have been studied for their potential to promote regeneration 
and repair, including Schwann cells, olfactory ensheathing glia, fetal spinal cord 
cells, and embryonic stem cells. In one group of experiments, investigators have  
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implanted tubes packed with Schwann cells into the damaged spinal cords of 
rodents and observed axons growing into the tubes. 
One of the limitations of cell transplants, however, is that the growth environment 
within the transplant is so favourable that most axons don't leave and extend into 
the spinal cord. Olfactory ensheathing glia cells, instead, natural migrators, are 
able to extend out axons of the initial transplant region and into the spinal cord but 
it’s not yet sure whether growth axons are completely functional.  
Recent discoveries describe the possibility to use neural stem cells (NSCs), 
progenitors of neuronal cells, in cell-mediated therapeutic protocols, for the 
regeneration and reconstitution of damaged tissues.  
Fetal neural stem cells (NSCs) transplantation was demonstrated to be very 
promising in the promotion of functional recovery after spinal cord trauma, and was 
associated with the differentiation of the stem cells injected into the cord [31][32]. 
Since the use of embryonic stem cells may raise ethical issues and practical 
problems such as the fate of the embryonic cells in adult environment and the 
required immunosuppression, the researchers have focused their attention on the 
adult neural stem cells [33]. 
Adult stem cells have been isolated from several adult tissues and other non-
embryonic sources, and have been demonstrated a surprising ability for 
transformation into other tissue or cell types and for repair of damaged tissues 
[34][35].  
The regenerative medicine and the stem cell research have as primary goal the 
regeneration and the replacement of dead or damaged cells. 
Several studies demonstrated the capability of NSCs to participate in repair of 
damage and their utility in the treatment of degenerative brain conditions [36]. For 
example, in Parkinson’s disease models, NSCs have been observed to integrate 
and survive for extended periods of time [37], and to rescue and prevent the 
degeneration of endogenous dopaminergic neurons [38].  
Transplanted embryonic SCs and fetal NSCs survive and improve functional 
recovery after SCI [31][39][32].  
Bottai et al. [40] have showed that adult NSCs, applied intraspinally or 
intravenously within 18 h after SCI, is able to counteract secondary degeneration 
and promote the recovery of function after acute SCI, as reported previously by 
Gorio et al. [41][1].  
Exogenous NSCs could be recovered live and regrown in vitro up to 7 d after 
administration; in addition, NSCs modified the lesion environment by promoting the 
expression of neurotrophic factors, and also produced the main enhancement of 
the rate of recovery during this initial period. Later, NSCs were phagocytated by 
macrophages, but the extent of functional recovery was maintained [32]. 
One of the big limit of NSCs transplantation is the inaccessibility of the cell source, 
that is located deeply in the brain, therefore the identification of a readily accessible 
source of neural progenitors (NPs) obtainable without invasive procedures could be 
of a great benefit. Several non-neuronal tissues can be used as source of adult 
stem cells capable of neuronal differentiation [42][43][44][45]. Recently it has been 
demonstrated that a multipotent stem cell population (dermis stem cell [DSC]) is 
present in the dermis of mammalian skin, and if grown in vitro it preferentially forms 
floating spheres made of cells positive for fibronectin and nestin [39]. 
 
 11 
 
3. LOCATION OF STEM CELLS IN THE CNS 
During the development of the CNS, stem cells localize within niches that are 
discrete anatomic zones. They have been identified in the dentate gyrus of 
hippocampus (SGZ) and in the subventricular zone (SVZ) along the lateral 
ventricles. Stem cells have also been found around the ependyma of the central 
canal and around the fourth ventricle. Other CNS niches include the hypothalamus, 
the optic nerves and the substantia nigra.  
During postnatal development, these mitogenic regions decrease in size and 
eventually disappear. The only remaining structure, that persists even after the 
development, is the SVZ, which, however, is reduced to a thin layer.  
Neural stem cells found in the CNS niches can proliferate along neuronal or glial 
lineage. Stem cell based repair occurs through the phases of multiplication, 
differentiation, migration and neo-synaptogenensis emerging form these sites.  
Cell proliferation is triggered by growth factors like FGF-2 (fibroblast growth factor) 
and EGF-1 (epidermal growth factor). During the CNS development, differentiation 
along neuronal lines occurs under the influence of Shh (Sonic hedgehog), while 
notch pathway guides proliferation towards a glial lineage. Shh, a secreted 
glycoprotein is involved in anterior motor neuron induction in the spinal cord. In 
adult rats too, Shh increases the proliferation of neuronal progenitors [46]. 
 
In the adult CNS, besides the action of FGF-2 and EGF-1, already useful during 
the CNS development, other mechanisms are involved in controlling cell fate 
towards the self-renewal capability or NSC differentiation. The CNTF (ciliary 
neurotrophic factor) cytokine, supports embryonic stem cell self-renewal capability 
and pluripotency [47], and, as recently observed, also supports NSC self-renewal 
capability triggering the Notch signaling pathway (figure 2) [48][49]. The transient 
activation of Notch, however, causes the rapid and irreversible loss of neurogenic 
capacity [50]. Moreover, most of the SVZ neural stem cells infected with Notch, 
eventually become periventricular astrocytes, suggesting the possibility that radial 
glia and astrocytes of the SVZ are of the same lineage [51][52]. and demonstrating 
that Notch signaling is instructive for the gliogenesis and the maintenance of neural 
stem cells in an undifferentiated state. Furthermore, the neurogenic development of 
SVZ was partly attributed to the mutual action of local antagonists such as Noggin 
and BMPs (bone morphogenetic proteins) [53]. The BMPs are a negative 
regulators of neuronal differentiation, while Noggin reverts this effect through its 
binding to BMPs, preventing the activation of their signal [54][55]. The BMPs are 
expressed by SVZ cells, whereas Noggin is expressed by the ependymal cells [53]. 
These interactions between ependymal and adiacent SVZ cells might provide for 
the neurogenesis and gliogenesis regulation in the adult brain. 
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Figure 2: Notch pathway and regulation of neuronal differentiation. 
 
 
So, in the CNS there are stem cells which have a potential to proliferate and there 
are factors which can induce their proliferation and guide the multiplying cells along 
various lineage. 
3.1. SVZ neural stem cells (NSCs) 
In the murine SVZ, there are three types of precursor cells: type B representing the 
GFAP (Glial fibrillary acidic protein) positive progenitors, type C (TAP transit 
amplifying progenitors) and finally the type A composed of migrating neuroblasts. 
The type B GFAP positive neural progenitors are less susceptible to antimitotic 
treatment and are relatively quiescent cells. 
The potential of SVZ progenitor cells appear to be limited, and the fate of their 
progeny is determined by positional information established in the early stages of 
CNS development [56].  
More in particular, in the SVZ there are two subtypes of mitotically active cells: 
neural stem cells (NSCs), which represent a relatively quiescent cell population 
with a cell cycle length of 28 hours [57][58] and TAP (transit amplifying precursors) 
progenitors with a cell cycle length approximately of 12 hours. The neural stem 
cells (NSCs) present in the SVZ, are responsive to epidermal growth factor (EGF-
1) or fibroblast growth factor (FGF-2) for the maintenance of staminality and self-
renewal capability [59][60].  
These growth factors are responsible of cell cycle length regulation: EGF-1 induced 
a faster cell proliferation than FGF-2 [61]. EGF-1 and FGF-2 may preferentially 
target one of these two different cell types [60][62]. Doetsch et al. have 
demonstrated that, intracerebroventricular infusion of FGF-2 into the lateral 
ventricle results in an increased number of new neurons in the olfactory bulb (OB), 
while the EGF-1 infusion reduces the number of neurons in the OB with a 
substantial increase in generation of astrocytes in the OB and striatum [62] even if 
other researchers have observed an equal increase in neurogenesis following 
FGF-2 or EGF-1 administration. 
The human SVZ is anatomically different from murine SVZ. It’s organized in four 
layers, where ependymal cells are separated by a ribbon of astrocytes because of 
a hypocellular gap [63]. In addition to ependymal cells, in the human SVZ are 
present three different types of GFAP positive astrocytes, and a very low number of  
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neuroblasts [64]. It’s interesting to note that no type C cells were identified in this 
region in humans.  
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4. LIMITATIONS OF STEM CELL THERAPY 
The use of stem cells in cell-mediated therapy is of considerable interest in 
research for the regeneration and reconstitution of tissues damaged by trauma and 
degenerative and inflammatory diseases. Numerous protocols include extraction of 
stem cells from healthy animals and implantation in diseased models.  
However, the evaluation of treatment efficacy, at the moment is based only on 
functional recovery that is possible just several months after the transplant. 
Furthermore, important variables such as the distribution of the injected cells, cell 
survival, target organ localization, cell proliferation and differentiation cannot be 
evaluated in vivo. All these variables are normally evaluated ex vivo, by means of 
immunohistochemistry, on bioptic samples and tissues from transplanted animals. 
The development of molecular imaging technologies (nuclear medicine, 
investigational radiology and optic imaging) permits to overcome these limitations 
providing refined methods for the in vivo visualization, in real-time, of specific 
molecular processes for in vivo study of biological processes associated with the 
use of cell-mediated therapies.  
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5. IN VIVO IMAGING 
In vivo imaging is a rapidly emerging biomedical research discipline that extends 
such observations in living subjects to a more meaningful dimension [65].  
The field of in vivo imaging offers the opportunity to define the morphological size 
and location of organs and diseased tissue and provides patient-specific 
information, for example, the tumour localization, staging and treatment follow-up 
response. Furthermore, the imaging techniques permit to couple these 
morphological datasets with functional biological pathways in an attempt to better 
understand the properties of specific organs.  
In medical research, in vivo imaging can be separated in molecular and cellular 
imaging depending on the object in study. These non-invasive techniques permit 
the characterization and quantification of targeted macromolecules and cells 
respectively, and of biological and cellular processes, at cellular and sub-cellular 
levels, in living organisms [65][66]. It is a novel multidisciplinary field, in which the 
images produced reflect cellular and molecular pathways and in vivo mechanisms 
of disease present within the context of physiologically authentic environments. 
The term “molecular imaging” implies the convergence of multiple image-capture 
techniques, basic cell/molecular biology, chemistry, medicine, pharmacology, 
medical physics, biomathematics, and bioinformatics into a new imaging paradigm 
[65].  
In vivo imaging technologies are based on computerized tomography (CT), 
magnetic resonance imaging (MRI), positron emission tomography (PET), single 
photon emission computed tomography (SPECT), scintigraphy and ultrasound 
(US) imaging. These techniques, previously used in human studies, have recently 
been redesigned for studies in small animals, whereas other techniques initially 
used for in vitro assays, including nuclear magnetic resonance (NMR), 
bioluminescence (BL) and fluorescence (FL) methods, have been refined for in vivo 
studies [67] (figure 3).  
 
 16 
 
 
 
Figure 3: Graphic representation of typical instruments available, and illustrative 
examples of the variety of images that can be obtained with in vivo imaging 
techniques: (A) microPET (B) microCT (C) microSPECT (D) fluorescence imaging 
(E) microMRI (F) bioluminescence imaging. 
 
 
Each technology is characterized by specific features: spatial and temporal 
resolution, penetration depth, energy used to generate the image, need/availability 
of contrast agents, threshold of detection. Furthermore, all these techniques differ 
for the type of information provided which could be, anatomical or functional. So, 
each methodology should be used with different efficiency, in relation to the 
application. 
 
There are three general categories of molecular imaging approaches in living 
subjects: direct imaging, indirect imaging and surrogate imaging [68]:  
• direct imaging: the image is the result of molecular probe localization at the 
target, directly and in a single stage. The extent of this localization (image 
intensity) relates directly to the interaction with the target, and each molecular 
probe is specific to one target.  
• indirect imaging: is based on reporter gene expression imaging. The cells or 
animals are engineered to express a gene codifying for a reporter protein, 
whose expression is easily detectable and quantifiable through imaging 
procedures, immunohystochemistry and enzymatic assays. The expression of 
the reporter is induced after the occurrence of a specific molecular event. 
Following that, a molecular probe (a substrate or a ligand) specific for the 
reporter protein (an enzyme or receptor) is used to image its expression. 
Different reporter genes have been used ranging from intracellular enzymes to 
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transmembrane transporter and receptors. In the case of stem cell studies, 
reporter genes could be used to image in vivo long term stem cell viability. For 
this purpose, reporter genes driven by constitutive promoters (e.g., 
cytomegalovirus or CMV, β-actin, ubiquitin), are usually used. On the other 
hand reporter genes driven by a tissue specific promoter (e.g. the neuronal 
promoter MAP2 or the muscular promoter Myogenin) can be used for the study 
of stem cell or progenitors differentiation.  
• Surrogate imaging: is also called ‘physiological’ or ‘metabolic’ imaging. These 
imaging strategies reflect downstream effects of the expression of one or more 
endogenous genes and/or molecular pathways involved in the metabolism, in 
order to describe the physiologic or pathologic conditions of tissues.  
 
The majority of current clinical applications of molecular imaging use the principle 
of ‘direct’ imaging, mainly because of the longstanding and established practice of 
probe or target development and the extensive use in clinical nuclear medicine. As 
evidence, most cell therapy protocols, [69][70][71], opted for direct labelling 
strategy for MRI because of its high resolution. Moreover, many contrast agents, 
e.g. magnetic nanoparticles like Endorem® with an iron-oxide core, are already 
approved for clinical use and can easily be translated for human cell labelling. 
 
 
 
 
Figure 4: Schematic representation of the direct and indirect imaging strategy.  
(a) Direct labelling procedures (b) Indirect imaging. 
 
 
Figure 4 displays the different phases of direct and indirect labelling: the 
advantages of direct imaging is the easy labelling protocols respect on the difficulty 
of engineering the cells [72]. In fact, the direct labelling consists of the aspecific 
internalization of a detectable agent (contrast agent or fluorescent probe) in a 
specific cell population or its specific binding to a molecular target in study. The 
great disadvantage of direct imaging, however, is that this approach does not 
enable long-term monitoring of cell viability and proliferation in the body because 
the label is lost or diluted owing to apoptosis or mitosis, respectively.  
The indirect approach, based on cell engeenering, is essential for the imaging of 
proliferating cell populations during their migration, activation and division in fact 
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modifying stem cells (SCs) or immune cells with a reporter gene the entire cell 
progeny can trap the reporter probe, without loss of labelling [72] (figure 5). 
 
 
 
 
Figure 5: Imaging of cell progeny over time. 
 
 
Molecular imaging in living subjects offers distinct advantages when compared with 
conventional in vitro and cell culture research techniques in biology. Although in 
vitro studies in basic biological research have been, and remain, a mainstay for 
defining biochemical and gene expression pathways, the in vitro approach has 
been less successful in deciphering physiological whole-body contributions of 
proteins, in which redundancies and differences in regulation can alter the outcome 
from that initially predicted [73]. In contrast to cell and tissue culture, in vivo animal 
models allow the assessment of phenomena such as tolerance, complementation, 
and redundancy in biological pathways [74]. Molecular imaging permits both the 
temporal and the spatial biodistribution of a molecular probe and related biological 
processes to be determined in a more meaningful manner throughout an intact 
living subject. Visualization of functions and interactions of a particular gene 
becomes easier in a more realistic manner that respects the dynamics of complex 
biological networks and of complete and holistic biological systems in the entire 
living subject [75].  
Furthermore, they allow a repetitive, non-invasive, uniform and relatively 
automated study of the same living subject using identical or alternative biological 
imaging assays at different time points, thus harnessing the statistical power of 
longitudinal studies, and reducing the number of animals required (according to the 
3R principle: Refine, Reduce, Replace) and cost. Moreover, each animal will be 
followed up as an individual being, thereby turning the cluster of animal models into 
an experimental group that can be compared directly with the treatment groups 
generally enrolled in clinical trials. 
5.1. Optical Imaging 
Optical imaging techniques reveal photons at different wavelengths (in visible and 
infrared ranges), resulting from bioluminescence (BLI) and fluorescence (FLI) 
events, by using highly sensitive charge-coupled device (CCD) cameras.  
CCD cameras operate by converting light photons at wavelengths between 400 
and 1000 nm that strike a CCD pixel with an energy of just 2–3 eV into electrons. A 
CCD contains semiconductors connected so that the output of one serves as the 
input of the next. In this way, an electrical charge pattern, corresponding to the 
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intensity of incoming photons, is read out of the CCD into an output register and 
amplified at the edge of the CCD for digitization.  
The thermal energy in the CCD chip results in constant electrons release (termed 
“dark current”), determining formation of background noise. This is dramatically 
reduced by cooling CCD chip: dark current falls 10 fold every 20° C decrease in 
temperature (e.g. for BLI imaging, CCD cameras are usually cooling to −120° C to 
−150° C).  
The derived image is a color image superimposed on a gray-scale photographic 
image of the small animal using overlay and image analysis software [76]. 
5.1.1. Bioluminescence imaging (BLI) 
BLI imaging is based on the use of reporter genes encoding enzymes able to 
produce emission of photons in the presence of specific substrates, in the 
wavelength range of 485-613 nm.  
The major limitation to the use of bioluminescent reporters is that the low energy 
photons emitted are absorbed and scattered in the tissue volume encountered on 
their path from the emission site to the detector system. It has been calculated that 
about 90% of the BLI signal is attenuated per centimeter of tissue depth. So, the 
amount of photons detected may not be proportional to the reporter expression or 
may be insufficient to visualize the enzymatic activity present in the most inner 
organs of the most common laboratory animals, including mice [77]. 
The most used reporter enzymes are Luciferases. After injection of a substrate, in 
presence of specific cofactors (e.g. Mg2+, oxygen, ATP, etc.), the substrate is 
oxydated with production of photons. Many Luciferases with matching substrates 
are available. 
The most useful Luciferase for molecular imaging is firefly (Photinus pyralis) 
Luciferase (and its substrate, D-luciferin). Firefly Luciferase catalyzes the 
transformation of its substrate D-luciferin into oxyluciferin in an oxygen and ATP-
dependent process, leading to the emission of photons with a peak wavelength of 
560 nm, and a wide emission that goes beyond 600 nm, characterized by a 
sufficient penetrance across small animal tissues. Furthermore, the non-
immunogenic substrate luciferin, either i.v. or i.p. injected, diffuses within minutes 
throughout the entire animal body and is rapidly taken up by cells. 
However, also Renilla Luciferase, green or red click beetle (Pyrophorus 
plagiophthalamus) Luciferases, and Gaussia Luciferase have been used. Both 
Renilla and Gaussia Luciferases emit blue light, which is highly attenuated in living 
tissue, and possess high bursting activity, therefore requiring care and precision in 
the readout timing. Moreover, their substrate, coelenterazine, has been shown to 
be transported by the multidrug resistance transporter Pgp as well as to interact 
efficiently with superoxide anion and peroxynitrate in light-producing reactions, 
thereby complicating applications of Renilla and Gaussia Luciferases in vivo [78]. 
Despite the ease of use, the low costs and the short acquisition time, this technique 
depends on pharmacokinetic of biodistribution of the substrate, does not provide 
fully quantitative data and in general offers mainly planar imaging datasets, 
therefore imposing some positional uncertainty of the attained signal.  
5.1.2. Fluorescence imaging (FLI) 
Fluorescent imaging is based on the detection of photons (wavelength range: 442-
800 nm) produced by the return to the ground state of electrons excited by laser 
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photostimulation. These photons can be revealed by CCD-camera by using 
specific filters to select excitation and emission band and to reduce noise 
background. In this technique the influence of tissue scattering and absorption is 
doubled compared to bioluminescent probes, because light must cover two-folds 
the signal-detector distance (excitation and emission pathways). 
Examples of fluorescent proteins are green fluorescent protein (GFP), red 
fluorescent protein (RFP). Despite largely used for in vitro study, not all these 
proteins are useful for in vivo studies, because of their photon wavelength 
emission, often under 600 nm. With the introduction of redshifted fluorescent 
proteins and injectable near-infrared fluorescent probes, the progression in highly 
sensitive photon detection device development and in vivo microscopy (confocal 
and multiphoton), and the advances in mathematical modeling of photon 
propagation in tissues it has been possible to develop innovative macro- and 
microscopic FLI imaging modalities such as FLI tomography, spectrally resolved 
whole body FLI imaging, and intravital multiphoton imaging [78]. 
In 2004 a report appeared describing new fluorescent reporters developed by 
mutagenesis process. These new genes were able to emit photons of several 
wavelength but with a more consistent set into the red spectrum. These proteins 
have emission maxima as long as 649 nm, but suffer from low quantum yields and 
then low brightness that limits their application in vivo [79]. 
In 2007 a brighter red-shifted fluorescent protein was described by Shcherbo et al 
[80]. This protein, named Katushka, is originated from the sea anemone 
Entacmaea quadricolor. Its excitation peak is at 588 mm and the emission peak is 
at 635 nm, both of which are relatively non-absorbed by tissues and hemoglobin. 
Katushka has many favorable properties in addition to its absorption and emission 
peaks, including a rapid maturation time of 20 min. Importantly, an extinction 
coefficient of 65 000 M-1cm-1 and quantum yield of 0.34 make Katushka the 
brightest fluorescent protein with an emission maximum beyond 620 nm. In cells, 
Katushka has no visible aggregates or other toxic effects.  
For what concern FLI, cell labeling is also possible with direct strategies. There are 
commercially available protein that are trapped by cell membrane, such as PKH26, 
VivoTag, Alexafluor [81], or fluorescent nanoparticles, such as Quantum Dots [82] 
[83]. These molecules offer certain advantages: faster labelling procedures and 
lower costs.  
Although exciting advances are emerging, FLI imaging still suffers from pitfalls 
such as, high autofluorescence in the blue-green window resulting in low signal-to-
noise ratios, fluorophore photo-bleaching, and high levels of photon attenuation 
and scattering in living tissues. However, imaging of fluorescent proteins 
(preferably monomeric red-shifted reporters) has an important advantage over 
other imaging modalities with genetically encoded reporters, i.e., no substrate is 
required, which uncouples read-out from substrate pharmacokinetic and thereby 
enables true real-time imaging. In addition, sub-cellular localization is possible by 
correlative microscopic analysis.  
5.2. Nuclear Imaging (PET/SPET) 
PET and SPET are both radionuclide imaging techniques, yet they differ 
substantially in the type of radionuclide employed to label the tracer and method of 
data acquisition [84]. 
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Both the techniques record high-energy γ-rays emitted from within the subject 
during a physical decay event occurring in instable nuclides. 
With regard to PET imaging, natural biological molecules can be labelled with a 
positron-emitting isotope. The most used isotopes are 15O, 13N, 11C, and 18F; other 
less commonly used positron emitters include 14O, 64Cu, 62Cu, 124I, 76Br, 82Rb, and 
68Ga. Natural decay of these radioisotopes produces emission of a proton from its 
nucleus, that annihilates with a nearby electron: this interaction is able to produce 
two 511 keV γ-rays that are emitted simultaneously about 180° apart. 
For SPET, single photon emitting isotopes (e.g., 99mTc, 111In, 123I, 131I) can be used 
for imaging living subjects. These radioisotopes are characterized by emitting 
photons of different energy (e.g. 111In decay with emission of two photons of 171 e 
245 keV, 99mTc with one photon of 140keV) [84][85]. 
 
Several molecules have been labelled with these radionuclides, to be used for 
classical applications. Once injected into the organism in study, they distribute with 
the blood stream and accumulate in relation to a specific process: perfusion, 
metabolism, receptor expression. 
Progresses have been made in developing more and more specific probes for 
every molecular target to be studied but a hard multidisciplinary work has to be 
done for each new tracer from the chemical synthesis, the labelling procedure, to 
the pharmacokinetic evaluation and the analysis of sensitivity and specificity as 
well as of its reliability. It takes many years before a new tracer can be used in 
every day life. 
 
 
Both PET and SPET imaging are highly dynamic methods permitting the study of 
biodistribution, localization and elimination of the tracer during time in the whole 
organism. 
Detection of γ-rays is achieved through an array of scintillation crystals able to 
convert γ-ray energy into visible light, suitable light sensors that convert light into 
electrons, read-out electronics, and image processing units.  
The coincidence detection of both γ-rays in PET within nanoseconds of each other 
defines the line of response in space and thus the direction of flight.  
The reconstruction software measures the coincidence events at all angular and 
linear positions to reconstruct an image that depicts the localization and 
concentration of the positron-emitting radioisotope within a plane of the scanned 
organ. 
In the SPET acquisitions, otherwise, to locate the source of an admitted photon, its 
direction of incidence into the detection system needs to be accurately fixed and its 
interaction location determined in the position sensitive detector. Lead or tungsten 
collimators are perforated plates that define the angle of photon incidence and are, 
therefore, positioned in front of the detector during SPET acquisition. Collimator 
design is a compromise between spatial resolution and sensitivity (see appendix 5 
for more details). 
In contrast to SPET, attenuation (quantifiable reduction in events present at the 
face of the detector due to absorption or scatter through tissues) of the emitted 
radiation in PET can be corrected precisely because the total length through the 
body determines the attenuation factor along a coincidence line. By doing so, 
quantitative information about the tracer distribution can be obtained. If single 
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photon emitters are used, the direction of flight has to be determined by geometric 
collimation.  
An important principle to note is that as all isotopes used result in two γ-rays of the 
same energy, if two molecular probes, each with a separate isotope, are injected 
simultaneously, it would not be possible for the PET detectors to distinguish them. 
Therefore, to investigate multiple molecular events, molecular probes are usually 
injected separately, allowing for the decay of one isotope prior to administration of 
the other. SPET, on the other hand, does allow simultaneous detection of multiple 
events owing to the use of multiple isotopes, each with different-energy γ-rays [65]. 
Several reporter gene systems have been developed for nuclear imaging studies. 
A well-studied strategy is the reporter gene hsv1-tk whose protein product (herpes 
simplex virus type 1 thymidine kinase [HSV1-TK] enzyme) can be imaged with the 
specific radiolabelled substrate (18F-fluoropenciclovir, 18F-FPCV) and imaged by 
PET imaging [86].  
Even if Iodinated substrates have been developed for the use of this reporter 
system in SPET imaging (FIAU, uracil nucleoside derivatives labeled with 
radioactive iodine) [87]. 
These radiolabelled reporter probes are transported into cells, and are trapped as 
a result of phosphorylation by HSV1-TK. When used in non-pharmacological tracer 
doses, these substrates can serve only for imaging without the well-known toxic 
suicide effects. More recently, a mutant version of this gene, HSV1-sr39tk, was 
derived using site-directed mutagenesis to obtain an enzyme more effective at 
phosphorylating ganciclovir (and also less efficient at phosphorylating thymidine) 
with consequent gain in imaging signal [88]. 
The Dopaminergic type 2 receptor (D2R) gene has also been validated for PET 
imaging as reporter gene. 18F-fluoroethylspiperone (FESP), a radiolabeled inhibitor 
of such receptor characterized by high affinity, can be used as reporter probe 
ligand [89].  
More recently, a mutant D2R that uncouples signal transduction while maintaining 
affinity for FESP has also been reported [90]. 
In SPET imaging, Na+/I- symporter has been largely used as reporter gene. In this 
case Iodide (123I-) is specifically transported into cells by the ATP-dependent 
symporter, and accumulated proportionally to the reporter expression level. 
Once transported into cells, 123I- is not modified and then is free to get out again 
from the cell. This is a drawback of the use of this symporter. It has been estimated 
that 80% of the 123I- transported by the NIS goes out from the cell during the first 
hour from the tracer administration [91] [92]. 
Moreover, it is possible to label cells directly for nuclear imaging by other strategy, 
besides gene reporter. Labelled molecular probes or tracers can be introduced into 
the subject, and then PET or SPET imaging can follow the distribution and 
concentration of the injected molecules. 
In this field, the most commonly used radiotracers are: 99mTc-HMPAO, 111Indio-
Oxine and 18F-FDG. These radiotracers are used for the ex vivo a-specific 
labelling of the cells that, once reinfused, can be followed by PET/SPET in vivo. 
One of the advantages of PET is that drugs or existing molecules known to interact 
with a specific target can be modified with a radiolabel while minimally perturbing 
the parent molecule. These probes serve quite a useful role in monitoring 
“downstream” changes in pathology, but do not generally serve to characterize 
changes early in a disease process. Currently, molecular imaging probes with 
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greater specificity and targeting potential can be made by using antibodies, 
ligands, or substrates that can specifically interact with targets in particular cells or 
sub-cellular compartments. One easy and useful molecule of this type is [18F-FDG], 
18F-2-fluoro-2-deoxyglucose. In the cells, this radioligand is phosphorylayed by 
hexokinase, providing information about cell metabolism. Despite the specificity of 
the molecular probes exemplified above, background noise can be substantial with 
this approach. This is because the scanner cannot distinguish the parent tracer 
from the bound or metabolized tracer, and as such, time is required to allow the 
parent tracer to clear. To circumvent this relative drawback, another category of 
specific imaging probes consists of activatable or “smart” probes (also referred to 
as sensors or beacons). These can only be detected once they have interacted 
with their target, and have been developed mainly for optical and magnetic 
resonance imaging applications [65].  
5.3. Magnetic Resonance Imaging 
MRI is widely used for imaging soft tissues. Nuclei (the most used is 1H due to the 
water’s abundance in the body) placed in a strong magnetic field align their spin to 
the magnetic field. Radiofrequency (RF) pulses induce some of the magnetically 
aligned nuclei to alter the alignment of their spins. When the RF pulse is turned off, 
the nuclei realign with the magnetic field, generating an electromagnetic flux that 
provides information about the environment of the resonating nuclei (for more 
details, see appendix 2 and 4).  
In animal models, different reporter genes have been studied by MRI. Principal 
feature of this type of labeling approach is the ability of reporter to modify the 
relaxing process of expressing cells. The most used reporter genes are based on 
the enzyme-based strategy [93]: 
1) enzyme-based cleavage of functional groups that block water (proton) exchange 
or protein binding of MR contrast agents, i.e. β-galactosidase. This enzyme is able 
to cleave off galactose to a gadolinium based substrate (EgadMe) and this results 
in inner sphere relaxation enhancement and increased contrast. A convenience of 
using β-galactosidase reporter system is the low background contrast, as there is 
no natural endogenous expression of the enzyme;  
2) expression of surface receptors that enable binding of specific MR contrast 
agents, i.e. transferrin receptor. After systemic injection of transferring-
monocrystalline iron oxide nanoparticles, this agents is retained to expressing 
receptor, generating a major contrast; 
3) expression of para- and anti-ferromagnetic (metallo)proteins involved with iron 
metabolism, such as transferrin receptor, ferritin and tyrosinase. For example, the 
last enzyme is part of the melanin synthesis pathway: it catalyzes the oxidation of 
tyrosine-yielding dioxyphenylalanine that is converted in melanin at the end of the 
whole process, that has high affinity for iron, accumulating it and generating a 
resonance signal [94]. 
On the other hand, to generate contrast in MRI, several contrast agents have been 
developed, also approved for clinical use. Among these agents T2-weighted iron 
oxide nanoparticles represent the most sensitive agent used in both animal and 
human applications. In general, any particle larger than 50 nm is termed 
superparamagnetic iron oxide nanoparticles (SPIO, as Endorem®), while particles 
smaller than 50 nm are called ultra small superparamagnetic iron oxide (USPIO). 
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Currently, SPIO is the only T2 contrast agent approved by FDA for MRI, and there 
are several reasons for its popularity. First, the particles are usually non-toxic to 
cells, and the particle is biodegradable in vivo. Second, it is a negative contrast 
probe, so it provides clear contrast to the background of the soft tissue, that 
generally are bright. Third, the particles can remain inside terminally differentiated 
cells throughout their lifetime, thus allowing long-term studies. Fourth, due to its 
sensitive signal, SPIO-based imaging requires a much smaller concentration than 
gadolinium, which makes SPIO more suitable for labelling human cells than other 
contrast agents [95]. 
SPIO-based MR imaging can be used for tracking diffent type of cells, including 
stem cells and progenitor cells. For not phagocytic cells, such as neural stem cells, 
a transfecting reagent may be required to load the particles. One examples id the 
addition of protamine sulphate, which is conventionally used in the clinic as 
antidote to heparin anticoagulation but also as a transfection agent in molecular 
biology [96].  
5.4. Application of Imaging in Cell Therapy 
In general, nuclear imaging modalities, such as SPET and PET, are highly 
sensitive (detecting fmol levels of probe), quantitative, inherently tomographic 
methods and can be used in humans. However, nuclear imaging demands 
sophisticated instruments, committed personnel, readily available in-house 
production of radiopharmaceuticals, and stringent dependency on tracer 
biodistribution.  
On the other hand, BLI imaging of Luciferase reporters provides a relatively simple, 
robust, cost-effective, and extremely sensitive means to image fundamental 
biological processes in vivo thanks to exceptionally high signal-to-noise levels, but, 
unfortunately, it is not translatable to human study. 
MRI is characterized by high spatial resolution and provides anatomical images, 
but its low sensitivity requires longer image-acquisition time and a higher amount of 
contrast agents. Moreover, the complexity of this technique requires the 
supervision of a specialized technician for instrument use.  
Furthermore, nuclear and optical techniques lack anatomical information, thus new 
scanners combined with computed tomography (CT) have been produced. 
 
With regard to  the stem cell tracking, the ideal imaging/agent should provide the 
following information:  
• Real-time visualization of stem cell delivery 
• Determination of location(s) of cells over time 
• Quantification of numbers of viable transplanted stem cells 
• Long-term quantification of transplanted stem cell survival 
• Study of interaction between stem cells 
• Study of interaction of stem cell with its microenvironment 
• Study of differentiation capacity of stem cells 
The chosen labelling modality should not interact with the normal functions of the 
stem cell. Otherwise, one would not be able to  study accurately the biology of 
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these cells over time. In addition, issues such as biocompatibility, toxicity, and 
safety not only to the stem cell but most importantly to the individual should also be 
considered, and included in the decision of which modality to use. 
All imaging modalities have a certain degree of background/non-specific signal 
(that may interfere with the signal under study). The preferred imaging modality 
should be one that provides a good contrast between background and the target 
signal under study, achieving a large signal-to-noise ratio. Furthermore, it should 
have good specificity (negative study in the absence of what is being studied, stem 
cells in this case). Only then it will be possible to use these modalities to study 
stem cell biology. 
The main objective of regenerative medicine, and thus of stem cell imaging, is its 
clinical application. It is generally agreed upon that before its clinical use, 
therapeutic strategies should be tested in clinical models of disease. Thus, an ideal 
imaging modality should be flexible across different imaging modalities, both in 
terms of spatial resolution and system sensitivity (the lowest amount of activity or 
numbers of cells that can be detected by that specific modality)[97]. 
As regards to the pharmaceutical research, the ideal molecular imaging technique 
should be characterized by high temporo-spatial resolution, high sensitivity, and 
high specificity, and it should also be translatable into the clinical setting. The ideal 
technology fulfilling all these criteria does not exist and compromises are to be 
searched for. There is increasing interest in constructing models that can be in vivo 
by means of different imaging modalities (multimodal imaging) combining the 
positive features of the single imaging techniques and overcoming their limits [94].  
Several studies were performed in cell therapy protocols and in immune 
therapeutic protocols. 
The development of stem or progenitor cell transplantation protocols for tissue 
regeneration and repair benefit greatly from in vivo assays that can rapidly assess 
the extent of cell survival and localization of transplanted cells. In the past years, 
these measures relied on histological analyses and required serial sacrifices of 
animals. That way, real-time data pertaining to cell migration and survival over time 
could not be assessed. Among the various imaging modalities that have been 
developed, several offer opportunities in this type of investigation. Magnetic 
resonance imaging (MRI) and fluorescence imaging provide means of tracking 
transplanted cells in vivo [98] [99] [100] [101]. 
Recent studies have revealed the effectiveness of neural stem or progenitor cells 
(NSPCs) transplantation in the treatment of Parkinson’s disease, multiple sclerosis, 
brain ischemia, and trauma of CNS, including spinal cord injury (SCI) [102] [103] 
[104] [105] [106] [107].  
Thanks to MRI techniques, Guzman et al. have demonstrated that human central 
nervous system stem cells, previously directly labelled with superparamagnetic iron 
oxide (SPIO), transplanted either to the neonatal, the adult, or the injured rodend 
brain respond to the cues characteristic for the ambient microenvironment resulting 
in distinct migration patterns.  
Politi et al., in a 2007 study, labelled with Resovist® the NPCs and monitored their 
accumulation following i.v. injection in mice with experimental autoimmune 
encephalomyelitis (EAE), the animal model of multiple sclerosis. With a human MR 
scanner, they were able to visualize transplanted cells as early as 24 hours 
posttransplantation in up to 80% of the brain demyelinating lesions. 
Neuropathological analysis confirmed the presence of transplanted NPCs 
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exclusively in inflammatory demyelinating lesions and not in normal-appearing 
brain areas providing evidence that clinical-grade human MR can be used for 
noninvasive monitoring and quantification of NPC accumulation in the central 
nervous system upon systemic cell injection [108]. 
Sykova and Jendelova studied the fate of implanted rat bone marrow stromal cells 
(MSCs) and mouse embryonic stem cells (ESCs) labelled with iron-oxide 
nanoparticles (Endorem®) and human CD34+ cells labelled with magnetic 
MicroBeads (Miltenyi) in rats with a cortical or spinal cord lesion. 
Cells were grafted intracerebrally, contralaterally to a cortical photochemical lesion, 
or injected intravenously. MRI images permitted to visualize labelled MSCs, ESCs, 
and CD34+ cells in the lesion as a hypointensive signal, persisting for more than 
50 days. These studies demonstrated that grafted adult as well as embryonic stem 
cells labelled with iron-oxide nanoparticles migrate into a lesion site in brain as well 
as in spinal cord. 
Several studies, conducted by De Vries et al [109] has recently shown the utility of 
the non-invasive MRI technologies also for monitoring, in humans, immune-therapy 
based on DCs previously matured and loaded with tumour-derived antigenic 
peptide. Together with other clinical and preclinical studies [110][111][112], this 
work demonstrated that the imaging of DC migration through MRI gives the highest 
spatial resolution among non-invasive modalities, with exquisite dynamic 
information and anatomical contrast [113]. 
The studies on animal models, using nanoparticles of iron oxide [114][115] 
permitted to demonstrate the potential for non-toxic labelling of haematopoietic 
bone marrow-derived and mesenchimal stem cell populations without affecting 
their transdifferentiation capacity. Iron oxide labelling can also be used to track 
smaller numbers of cells in homing experiments enabling the in vivo identification 
of the mesenchimal stem cells which migrated to infarcted myocardium after 
intravenous administration.  
Adult farm pigs were subjected to experimental MRI, and MSCs were injected 
intramyocardially under x-ray fluoroscopy. The labelled cells could be detected in 
the myocardium, with different shapes because of the different distribution in the 
damaged organ [114]. In the cardiovascular setting, besides, this cell labelling 
technology could be coupled with direct delivery methods through endomyocardial 
injections, demonstrating that transplanted cells could be imaged shortly after 
delivery with a high degree of spatial resolution using MRI [114].  
With regard to the direct labelling for optical imaging, Hoshino et al [116] reported a 
successful labelling of bone marrow–derived mesenchimal stem cells with IR-786 
(a NIR fluorophore) and their subsequent in vivo tracking for 90 minutes after 
intracoronary cell injection in a swine model of myocardial infarction. 
The imaging in the NIR window (700-900 nm) has the advantage to be 
characterized by low absorption by intrinsic photoactive molecules, thus allowing 
light to penetrate several centimetres into the tissue giving the possibility to be 
used in big animals.  
Gorio et al. [33] have labelled stem cells from dermis with PKH 26, a stable cell 
membrane fluorescent labelling, in order to localize them after their transplant into 
gracilis and cuneate fascicle at 3 mm caudally or rostrally to the spinal lesion site. 
The cell labelling permitted to demonstrate that when cells were transplanted into 
the spinal cord after traumatic injury, they were able to migrate into the lesion 
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cavity but their differentiation was dependent upon the time interval between 
lesioning and cell transplantation (submitted paper or Data not yet published). 
In spite of MRI and fluorescent imaging are very useful in tracking transplanted 
cells in vivo, these techniques can be constrained by sensitivity and/or retention of 
the label [117][118][119]. 
 
The first imaging data on stem cell therapies by nuclear imaging and in particular 
by SPET and 111In-oxine, were based on the intravenous injection of labelled MSCs 
[120][121]; the data allowed to conclude that the radiolabelling of MSCs is feasible, 
providing a good spatial resolution, but, as a consequence of the significant lung 
activity due to i.v. administration of MSCs –which obscures the assessment of 
myocardial cell trafficking- alternative routes of administration should be 
investigated for this application [120]. When 111In111–labelled endothelial progenitor 
cells were injected intraventricularly in the infarcted rat myocardium, labelled cells 
were found to accumulate in the hearth, but the overall radioactivity in the organ 
was only around 4.7% of the injected dose [122]. These data suggested that in 
loco injection is an efficient route of administration and that only a small number of 
cells ultimately home to injured myocardium, corroborating the high sensitivity of 
the nuclear imaging technique. 
Several studies in the field of neuroscience reported the possibility to track also 
neural stem cells or progenitors by the use of nuclear imaging techniques. 
Lappalainen et al. demonstrated, in 2008, using the SPET imaging, the 
accumulation of neural progenitor cells into internal organs after systemic 
administration in middle cerebral artery occlusion rats [123].  
In this work they evaluated the feasibility of small animal SPET/CT in assessing the 
definite accumulation of 111In-oxine-labeled human embryonic stem (ES) cell-
derived neural progenitors and rat hippocampal progenitors after intravenous or 
intra-arterial administration (femoral vein vs. common carotid artery) in middle 
cerebral artery occlusion (MCAO) and sham-operated rats. Cell detection was 
carried out immediately and 24 h after the infusion using a SPET/CT device. 
The results permitted to demonstrate that after intravenous injections both cell 
types accumulated primarily into internal organs, instead of brain. In contrast, after 
intra-arterial injection, a weak signal was detected in the ischemic hemisphere. 
These data showed that the small animal SPET is a powerful technique to study 
the whole body biodistribution of cell-based therapies and that intravenous 
administration is not an optimal route to deliver neural progenitor cell-containing 
transplants into the brain after MCAO in rats. 
 
To circumvent the problem of signal loss due to dilution with cell division, typical of 
the direct labelling techniques, the research is focusing its attention on the reporter 
gene techniques. The aim is to integrate a reporter gene into the cells before 
transplantation. Such an approach that has been used for cell tracking and survival 
studies uses cells labelled with the luciferase gene and instruments for BLI [124], 
as described in the previous paragraph (5.1). BLI has been shown to be a useful 
tool for tumour, immune, and hematopoietic cell tracking studies. Usually, third-
generation self-inactivating lentiviral vector system based on human 
immunodeficiency virus type 1 (HIV-1) is used. This viral vector offers safe, high 
titer transduction and efficient integration into cells irrespective of their state of 
division [125][100][126]. 
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Okada et al., in order to monitor engrafted neural stem cells in the spinal cord 
injury, used a lentiviral vector to achieve efficient delivery and stable expression of 
both luciferase and green fluorescent protein (GFP) in primary cultured NSPCs. To 
determine the optimal timing of transplantation for SCI, they transplanted 
transfected NSPCs at different times relative to injury and observed differences in 
survival, migration, and differentiation of NSPCs.  
In other studies based on bioluminescence imaging, embryonic rat H9c2 
cardiomyoblasts expressing Firefly Luciferase as reporter gene were injected in the 
myocardium of rats [127]. Drastic reductions of signal intensity were noted within 
the first 1 to 4 days after transplantation, probably because of acute donor cell 
death following inflammation, ischemia, and apoptosis, as displayed on the 
histology, but the signal was detectable until 16 days. 
Reporter constructs with luciferase are also useful for the study of cell 
differentiation as described by Hawang et al. They imaged neuronal differentiation 
in vivo of F11 cells using dual reporters (sodium iodide symporter [NIS] and 
luciferase) coupled to a neuron-specific enolase (NSE) promoter [128].  
 
The direct cell labelling is simple and allows to visualize the location of the 
therapeutic cells nevertheless it is not sufficient to permit a long-term study of 
variables such as cell survival and differentiation, that, instead can be monitored in 
vivo by the use of reporter genes and adequate promoters. 
The combination of the two techniques would allow long-term studies useful for the 
therapeutic protocol set up. Furthermore it would allow the identification of early 
and intermediate checkpoints giving information about the progress of the 
treatment by the use of diagnostic procedures that can be translated into clinical 
use.  
Regarding the choice of imaging techniques, a combination of different techniques 
would overcome the limitations of individual methods by providing more informative 
results. 
In particular, the BLI for animal models together with MRI transferable to the clinic, 
would be the best solution because it would combine the high sensitivity of BLI and 
its ease of use with high spatial resolution of MRI. The development of even more 
efficient contrast agents and the use of ever higher magnetic field intensity 
scanners would also permit to obtain an even better sensitivity with the advantage 
to be clinically transferable. 
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The use of stem cells in cell-mediated treatments is of considerable interest in 
research for the regeneration and reconstitution of tissues damaged by trauma and 
degenerative and inflammatory diseases. Continuous progresses have been made 
in the ability to isolate stem cells, culture them and track their differentiation in vivo. 
Moreover, numerous treatment protocols have been tested in various animal 
models in which stem cells are extracted from healthy animals and implanted in 
diseased ones.  
At the moment, one of the limits of stem cell therapy consists of the fact that 
treatment efficacy evaluation is based only on functional recovery several months 
after the transplant also by the use of classical imaging techniques.  
Furthermore, important variables such as the distribution of the injected cells, 
target organ localization, cell survival, proliferation and differentiation cannot be 
evaluated in vivo with conventional techniques. All other variables listed here are 
evaluated ex vivo on samples from biopsies and tissues from transplanted animals 
by means of immunohistochemistry.  
For these reasons, the aim of this study was the introduction of early check-points 
permitting the in vivo evaluation of cell localization after transplant using cell 
imaging techniques. In particular, we proposed the development of protocols for 
the in vivo visualization of mNSCs in the evaluation of treatment approaches of 
traumatic spinal cord injury.  
By using imaging techniques, such as nuclear imaging (PET/SPET), magnetic 
resonance imaging (MRI), and optical imaging (BLI and FLI), the fate of the 
injected cells can be dynamically and functionally evaluated in vivo in space and 
time, permitting to define specific parameters for assessing treatment efficacy in 
the early phases. The imaging protocols provide objectively evaluable parameters 
for describing the progress of a cell-mediated therapy, so to correlate the 
distribution, survival, effective differentiation of the injected cells with functional 
recovery in vivo over time by combining anatomic findings with functional results.  
The use of different imaging modalities has the advantage to combine the positive 
attributes and to overcome the limits of the single imaging techniques themselves. 
Furthermore with these protocols, the number of needed experimental animals 
would be lower, thus reducing interindividual variability, since each animal would 
become its own control. In addition, with fewer animals and better evaluation, the 
number of stem cells needed per experiment could be reduced, making them 
available for further studies.  
 
More in particular, in the course of this project, neural stem cells were isolated from 
the subventricular zone of adult CD1 mice brain and implanted into spine-injured 
animals models. The cells were directly labelled with magnetic particles or 111In-
Oxine for Magnetic resonance imaging (MRI) and nuclear imaging respectively. 
Early phases distributions were followed by scintigraphy while MRI. The cells were 
also indirectly labelled. NSCs were infected with a lentiviral vector containing 
Luciferase controlled by the PGK constitutive promoter. Bioluminescent imaging 
(BLI) provided information about cell distribution, and luciferase activity permitted in 
vivo evaluation of cell viability after transplant. All the information provided by the 
different in vivo imaging analyses will permit the direct evaluation of treatment 
efficacy in each single animal permitting to foresee eventual adjustments of the 
protocol for each single treated subject.  
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Materials and Methods 
 32 
 
1. MURINE NEURAL STEM CELLS (mNSCs) COLTURE 
Adult CD-1 albino mice weighing 25-30 g (Charles River) were anesthetized by 
intraperitoneal injection of 4% chloral hydrate (0.1 ml/10 gm body weight), then 
sacrified by cervical dislocation and neural stem cells were isolated as described 
by Gritti et al. [61]. Tissues were enzymatically digested at 37°C for one hour in 5% 
CO2 in a solution containing cistein (Sigma) 0.2 mg/ml, EDTA (Sigma) 0.2 mg/ml 
papain (Worthington DBA) 1 mg/ml in EBSS (Enhanced Balanced Salt Solution) 
(Gibco). At the end of the digestion the tissue was spun at 123 g for 10 minutes, 
the supernatant removed and substituted with 1 ml of EBSS medium. The pellet 
was desegregated using a 1000 µl Gilson pipette, washed in EBSS and centrifuged 
with the same parameters of the previous one. The supernatant was removed 
leaving 200 µl and the pellet further desegregated by pipetting up and down with a 
200 µl Gilson pipette and wash with EBSS and further centrifuged at 123 g for 10 
minutes. The supernatant was finally discarded and the pellet re-suspended in 200 
µl of medium containing EGF (20ng/ml)(Epidermal Growth Factor), bFGF (10ng/ml) 
(basic Fibroblast Growth Factor), DMEM/F12 medium 2 mM L-glutammine, 0.6% 
glucose, 9.6 gm/ml putrescine, 6.3 ng/ml progesterone, 5.2 ng/ml sodium selenite, 
0.025 mg/ml insulin, 0.1 mg/ml transferrin, and 2 mg/ml heparin called growth 
medium. The cells were plated as 3500 cells/cm2 in the appropriate volume of the 
aforementioned medium in a 25 cm2 flask at 37°C in a humidified 5% CO2 
atmosphere. EDTA (Sigma-Aldrich), and incubated for 45 min at 37°C on a rocking 
platform. Tissues then were centrifuged at 123g and the supernatant was 
discarded. The pellet was re-suspended in 1 mL of EBSS and mechanically 
dissociated using an aerosol resistant tip (1000 µm Gilson Pipette). Cells were re-
suspended in 10 mL EBSS and centrifuged at 123g for 10 min. The supernatant 
was discarded and the pellet re-suspended in 200 µL of EBSS. The pellet again 
was dissociated mechanically using an aerosol resistant tip (200 µm Gilson 
Pipette). Cells were re-suspended in 10 mL of EBSS and centrifuged at 123g for 10 
min. The supernatant was discarded and the pellet resuspended in 1 mL of 
chemically defined DMEM-F-12 containing FGF2 (human recombinant, 10 ng/mL; 
Peprotech, Rocky Hill, NJ, USA, or Upstate Biotechnology, Lake Placid, NY, USA) 
and EGF (human recombinant, 20 ng/mL; Peprotech). The cells were counted and 
plated at 3500 cells/cm2, the spheres formed after 5–7 d were harvested, collected 
by centrifugation (10 min at 123g), mechanically dissociated to a single-cell 
suspension, and re-plated in medium containing the appropriate GF(s) (19). This 
procedure was repeated every 3–5 d (passage) in vitro for up to 12 months. The 
total number of viable cells was assessed at each passage by Trypan blue 
exclusion. Stem cells used in these experiments were between the fifth to the 
fifteenth passage in culture. 
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2. NSCs LABELLING 
2.1. Direct labelling 
2.1.1. NSC labelling with SPIOs 
Murine neural stem cells (mNSC) were freshly plated early in the morning. Six 
hours after, cells were labelled with different amounts of SPIOs (0 - 100 - 200 - 400 
µg Fe/ml Endorem, Guerbet®; stock solution 11,2 mg Fe/ml) in the colture medium 
and incubated for 24,48 or 72 hours in presence of transfection agents such as 
PLL hydrobromide (Sigma-Aldrich; a stock solution at 2,4 mg/ml), polybrene (PB, 
Sigma-Aldrich; stock solution 10 mg/ml, used at 10 µg/ml) and protamine sulphate 
(PS, Sigma-Aldrich; stock solution 10 mg/ml). PLL and PS were tested at different 
ratio (Fe/PLL 1:0,03, 1:0,06 and 1:0,09 and Fe/PS 1:0,025 and 1:0,05). Cells were 
washed three times with PBS and Heparin (1U/ml).  
After 24, 48 and 72 hours of incubation, cells were counted to analyse the viability 
by standard Trypan Blue exclusion test and then washed. Morphology (Perl’s 
staining), iron content, and relaxation time reduction were analysed to evaluate the 
labelling efficiency and the capability of the cells to be detected in vivo by MRI. Part 
of the labelled cells were also plated and cultured for further 5 or 7 days for 
multipotency and differentiation capability analyses, respectively.  
2.1.1.1. Perl’s Prussian Blue Staining 
After incubation with paramagnetic nanoparticles, the Prussian blue (PrB) staining 
(Perls’ acid ferrocyanide) was used for the detection of iron within the cell cultures. 
This induces a reduction of ferric iron to the ferrous state with formation of a blue 
precipitate.  
150.000 single-cell-dissociated SPIO-labelled NSCs harvested on glasses for 
microscopy using cytospin, were fixed with an alcoholic solution (Cervix fixative, 
J.T Baker). Prussian blue (PrB) staining was performed by incubation in a 1:1 
mixture of 2% HCl (BDH Laboratory Supplies) and 2% potassium ferrocyanide 
(Merck) for 45 minutes at room temperature (24°C). A minimum of n° 7 
nonoverlapping fields was counted for each sample. Cell membranes were 
counterstained by gram’s Safranine solution (Merck). Data were expressed as 
mean percentage of PrB-positive cells (over total of counted cells).  
2.1.1.2. Iron content evaluation 
The iron content per cell was evaluated with the spectrophotometer analysis [129]  
The absorbance (optical density) was measured using a Hewlett Packard 8452A 
diode array spectrophotometer (Hewlett Packard, Palo Alto, CA, USA).  
2.1.1.3. Relaxation time measurements 
Cells were washed as described above and then every sample was resuspended 
in 500 µL of 1%PFA at the same concentration. 2.5 ml of PBS were added and the 
samples were analysed at 40°C using a 0.47-T Bruker Minispec mq20 relaxometer 
(see 1.3.3 paragraph and appendix 2 and 3 for details) with the following 
parameters: 12.000 pt reading single scan, delay of 2 sec, gain of 64, dummy shot 
of 0.  
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2.1.2. NSC labelling with 111In-oxine 
1x106 cells were incubated for 30 minutes with 60 µCi of 111In-oxine and Tris-HCl 
5M (pH7) buffer. The cells were washed in PBS and injected into the tail vein of a 
spinal cord injured mice. 
2.2. Indirect labelling 
2.2.1. Lentiviral production 
Helper Lentiviral vectors of third generation (pMD2g-VSV-G, pMDLg-RRE and 
pRSV-Rev) useful for the viral production for stem cells infection were offered by 
Dr. Rivella’s Laboratory (Cornell University, New York) and were amplified in DH-
5alpha bacteria (NEB), purified with an endotoxin free DNA extraction kit 
(Invitrogen) and diluted in TE buffer. 
The pCLL.PGK.Luc.WPRE (PLW) plasmid, containing the Luciferase gene 
controlled by the constitutive promoter PGK, was previously cloned in our 
laboratory. 
The lentiviral vectors were producted as described by Tom Dull et al. [130]. 
The vector copy number (VCN) viral titer (7,62x105 TU/ml) was calculated on HeLa 
cell lines through the amplification of the lentiviral specific WPRE region from 
genomic DNA of Hela infected cells by the use of the Real-Time PCR technique 
[131] and its comparison to a curve of DNA standards with known VCN.  
2.2.2. NSCs Infection 
NSCs were infected with 5 MOI of PLW lentiviral vectors and polybrene (8 µg/ml). 
The luciferase expression was evaluated after the cell lysis, by CCD camera using 
a luciferase activity assay (Promega) and the data obtained were normalized on 
the total protein concentration. 
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3. EVALUATION OF LABELLED NSC FEATURES 
3.1. Stem cells features maintenance 
The maintenance of the capability of labelled NSCs to form new neurospheres was 
visualized by optical microscopy while the maintenance of specific neural stem 
cells marker expression was evaluated in immune-Fluorescence.  
180.000 labelled NSCs were dissociated to a single-cell suspension, were 
harvested on glasses for microscopy using cytospin, and were fixed with an 
alcoholic solution (Cervix fixative, J.T Baker).  
NSCs were permeabilyzed by a solution TRITON 0,1 % and PBS 0,01M (200 
µl/well) and incubated with the primary antibodies anti-nestin (monocl.1:100; 
Pharmingen, San Jose, CA, USA)). Nuclei were stained with DAPI. The detection 
of immunocomplexes was performed using the appropriate secondary antibodies 
conjugated with either Texas Red or fluorescein isothiocyanate (Jackson 
Immunoresearch Laboratories).  
3.2. Cell differentiation 
The neural differentiation was evaluated by Immune-fluorescence for GFAP 
(marker of astrocytes), Gal-C (marker of oligodendrocytes) and β-tubulin III 
(neuronal marker) expression. 
NSCs, after the dissociation were plated, at the density of 40,000 cells/cm2, on 
coverslips pre-coated with adhesion molecules (Matrigel™) placed into the wells of 
a 48 multiwell plate. The NSC differentiation was achieved colturing stem cells in 
presence of serum and removing the growth factors (EGF and FGF). Differentiation 
and expression of various epitopes were achieved within 7 days. Differentiated 
NSCs were fixed with 4% paraformaldehyde in PBS for 5 minutes at room 
temperature, and, then, washed with PBS. Cells were used for 
immunocytochemical staining. 
The immunostaining was performed as follows: the coverslips were incubated for 
90 min at 37°C (or overnight at 4 °C) in PBS containing 10% normal goat serum 
(NGS), 0.3% Triton X-100, and the appropriate primary antibodies or antisera. After 
thorough washing with PBS and 10% NGS, cells were incubated for 45 minutes 
(room temperature) with secondary antibody (anti mouse or rabbit) conjugated with 
the Alexa Fluor dyes 488 or 543nm (Invitrogen, Carlsbad, California). The cells 
were then counterstained with the DNA-binding dye 4'-6'-diamidino-2-phenylindole 
(DAPI) (2 µg/ml in PBS) for 10 minutes at room temperature, twice washed in PBS 
followed. Coverslips containing the stained differentiated cells were mounted onto 
glass slides and examined under a fluorescence microscope (Leica, Wetzlar, 
Germany). Acquisition of the stained cells was performed using the image-analysis 
software (Leica, Wetzlar, Germany ) or by confocal microscope Leica SP2 
microscope with He/Kr and Ar lasers (Leica, Wetzlar, Germany). In control 
experiments, primary antibodies were either omitted or replaced with equivalent 
concentrations of unrelated IgG of the same subclass. Moreover, in double 
labelling experiments, sections incubated with one primary antibody and two 
secondary antisera revealed no appreciable cross-reactions. 
Neural differentiation was assessed by immunocytochemistry with antibodies 
against: β-tubulin III (monocl. 1:100; Sigma), microtubule-associated protein 2 
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(MAP-2; monocl. 1:200; Sigma), glial fibrillary acidic protein conjugated with cy3 
fluorocrome (GFAP-cy3; monocl. 1:50; Roche, Basel, CH). 
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4. SPINAL CORD INJURY 
4.1. Animals 
Adult CD1 mice weighing 28 to 30 g were used. A standard dry diet and water were 
available ad libitum. All experimental protocols were approved by the Review 
Committee of the University of Milan and met the Italian guidelines for laboratory 
animals, which conform to the European Communities Directive of November 1986 
(86/609/EEC)  
The animals were kept for at least 3 d before the experiments in standard 
conditions (22 ± 2° C, 65% humidity, and artificial light between 08:00 a.m. to 08:00 
p.m.). 
4.2. Spinal Cord Injury with UTS Impactor 
The traumatic SCI was performed by means of the UTS impactor as described by 
Gorio et al [5 ]. 
Animals were previously anesthetized by i.p. injection (10 ml/kg) of 4% chloral 
hydrate (Sigma-Aldrich, St. Louis, MO) and laid over a mat kept at the temperature 
of 38°C.A laminectomy of the T8 and T9 vertebral level was performed on 
anesthetized mice. The lateral processes of T8 and T10 vertebras were cleared of 
the muscle to allow the stabilization of the vertebral column using forceps attached 
to the impactor-clamping platform, and a contusion injury was induced on the 
exposed cord using the impactor device. The impounding piston was positioned 1 
mm above the exposed cord at T8 and T9 and set for an excursion of 3 mm. A 
force of 50 Kd for 2 seconds was applied, which was followed by an automatic 
return of the impactor rod. The muscle and skin were sutured, after the injury, with 
a reabsorbing string (Etichon).  
Before awakening, they were treated with buprenorphine (0.03 mg/kg) (Sigma- 
Aldrich) for pain and penicillin G (10,000 U/kg; Sigma-Aldrich) as antimicrobial 
agent. 
To prevent the sepsi post-operation, in the next days all mice were treated with 100 
ml of subcutaneously injected ampicillin (100 mg/Kg, Farmitalia) and 1 ml of 
physiologic solution. 
Each experimental group was constituted by at least 15 animals. 
4.3. Experimental Groups for Transplantation 
The animals were divided into four experimental groups: 1) spinal cord injured CD1 
mice injected with 1,5x105 of labelled NSCs directly into the spinal cord used as 
positive control; 2) spinal cord injured CD1 mice injected with 1x106 of labelled 
NSCs into the tail vein; 3) Naïve control mice not laminectomized and not injured; 
4) spinal cord injured mice transplanted with phosphate buffer (PBS) by i.v.(Mock 
mice).  
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5. IN VIVO IMAGING 
5.1. Nuclear Imaging 
Nuclear imaging of the early phases distribution was performed, on the four 
experimental groups, for 3 days soon after the injection of 111In-I-oxine labelled 
cells using a new very compact gamma camera prototype (Hi-Cam), developed in 
collaboration with the Politecnico of Milan, constituted by Silicon Drift Detectors 
(SDD) and characterized by a high spatial resolution (< 1mm), a FOV of 5x5 cm2 
and a Sensitivity of 272 cpm/microCi using a parallel hole collimator and of 282 
cpm/microCi using a Pin hole collimator.Being Hi-Cam a prototype, no standard 
acquisition sequences were available: for each image, timing of acquisition was 
depending on the radioactivity of the injected cells. 
5.2. MRI 
After the incubation with the SPIO-containing medium, cells were washed twice in 
phosphate-buffered saline (PBS), and once in PBS added with heparin (1U/ml) and 
viable cells were counted by trypan blue exclusion. 
All mice were previously anesthetized with an intraperitoneal injection of 4% 
Chloralium solution. Then cells or PBS were injected into the spinal cord or into the 
tail vein of the injured mice. The injection was performed the same day of the injury 
in every experiment. 
MRI imaging was performed, on the four experimental groups, from 1 week after 
the transplant up to 2 months using 7T MR scanner (Bruker). 
Anesthetized animals (isofluoran gas anaesthesia) were positioned prone on the  
animal bed and inserted in the radiofrequency coil (diameter of 38 mm) inside the 
magnet. Scout transverse images were acquired for correct positioning of interest 
region. Different MR sequences were tested in order to optimize spinal cord 
visualization and signal contrast: 
• Spin Echo (MSME) sequence, (matrix 256x128; TR/TE: 1200/12 ms; 2 
averages; acquisition time: 5' 7''; fat suppression used) permitted to obtain 
images for morphological analysis of tissues and organs,  
• Gradient Echo (FLASH) sequence (matrix 256x128; TR/TE: 1200/10 ms; 2 
averages; acquisition time: 5' 7'') permitted to enhance the iron signal, with a 
decreasing on morphology definition.  
• Fast spin echo (RARE) sequence (matrix 256x128; TR/TE: 2000/56 ms; e 
average; acquisition time: 4’16’’) permitted to enhance the iron signal 
maintaining a good morphological resolution. 
All animals were acquired in sagittal, coronal (5 slices of 0.7 mm of thickness; FOV 
4x4 and spatial resolution of 156 µm x 312 µm) and axial plans (12 slices of 0.7 
mm of thickness; FOV 3x3 and spatial resolution of 117 µm x 234 µm). 
Once a week a small group of animals were sacrificed and the spinal cords were 
collected, embedded in formalin and sectioned, in order to perform Perl’s staining, 
as described above. 
Sections of the spinal cords were analysed by optical microscopy at 5X, 20X and 
40X original magnification to confirm the homing of labelled NSCs.  
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5.3. In vivo Bioluminescence imaging (BLI)  
The NSCs were infected with the PLW lentiviral vector and analyzed for cell 
viability and for the maintenance of phenotypical and functional features as 
previously described. 
Xenogen-IVIS Lumina cooled CCD optical macroscopic imaging system was used 
for BLI after an i.p. injection of D-luciferin (80 mg/kg body weight). Mice injected 
with lentivirally infected mNSCs were acquired every day, for the first week after 
the transplant and then once a week for a month. Serial images were initially 
acquired from 5–35 min after D-luciferin administration in order to find the time 
window providing the maximum signal intensity. Since the signal intensity peaked 
at 15 min after D-luciferin administration, followed by a plateau of 25 min, this time 
window was chosen for the next acquisitions. Naïve control mice not 
laminectomized and not injured and mock mice were acquired as negative controls. 
All images were analyzed with Living Image software (Xenogen). 
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6. STATISTICAL ANALYSIS 
Statistical analysis was performed with a Student’s t test. For the open field score, 
repeated. measure ANOVA and Bonferroni/Dunn test were used. Significance was 
accepted at P < 0.05. 
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Results and Discussion 
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1. NSCs DIRECT LABELLING FOR MRI 
1.1. NSC labelling with SPIOs 
In CNS disorders characterized by neuronal or glial loss (e.g. Parkinson’s disease, 
Multiple sclerosis, stroke and spinal cord injury), the NSC-based replacement 
therapies represent a promising alternative therapeutic approach. However there 
are some relevant issues that needed to be solved before translating such 
therapies to human application: 1) the route of cell administration and cell homing; 
2) persistence and the differentiation of transplanted cells into the targeted tissue. 
Furthermore, the integration of transplanted cells into the host tissue and the 
maintenance of cell viability and functionality are important goals to be achieved. 
To better understand these events for a future translation in humans of such 
promising therapies the research would benefit from a reliable non invasive 
imaging system able to follow in vivo the fate of transplanted cells. 
Among the different imaging techniques, MR imaging presents numerous 
advantages, since it offers both near-cellular (i.e., 25-50 µm) resolution and whole 
body imaging along with excellent soft tissue contrast. MRI is characterized by a 
high spatial resolution and a direct anatomical correlation, which permits relatively 
precise localization of transplanted labelled cells. Furthermore this technique is still 
commonly used in clinical practice and in particular for the study of human CNS 
and represents a good tool for diagnosis, patient examination and monitoring. 
In order to develop a methodology for the in vivo monitoring of murine adult NSC 
trafficking, we set up a specific labelling protocol with paramagnetic nanoparticles 
(MNPs) and analyzed the maintenance of their phenotypical and functional 
features once incubated with paramagnetic nanoparticles such as new 
neurosphere formation and the maintenance of differentiation capability. 
Commercial MNPs, called Endorem® (FDA approved), are formed by a core of iron 
coated with dextran (called ferumoxide) with an hydrodynamic ray of about 100 
µm. These MNPs can be resuspended in cell colture medium and internalized by 
NSCs. 
Cell labelling was carried out by either direct exposure of the cells to the SPIOs 
(Endorem, Guerbet ®) or by complexing the SPIOs to different carriers such as 
poly-L-lysine (PLL), polybrene (PB) and protamine sulphate (PS). To further 
optimize the loading protocol also different times of incubation of the cell with the 
iron containing colture medium were used. 
Labelling efficiency was calculated by analyzing the percentage of cells positive to 
the specific iron staining Perl’s while cell viability after labelling was evaluated by 
the Standard Trypan Blue Exclusion Test.  
In preliminary studies, murine NSCs, were incubated for 24h with different amount 
of SPIOs (25–50–100-200-400 µg Fe/ml, Endorem ®). After the Perl’s staining, it 
was possible to observe an increase in iron content per cell in relation to the iron 
concentration in the medium and to the different carriers (figure 1 and graph 1). 
The incubation with SPIOs in presence of polybrene or PLL also tested at different 
ratios with respect to the nanoparticles (Fe/PLL 1:0.03; 1:0,06; 1:0,09) didn’t 
increase the labelling efficiency (data not shown), on the contrary the use of PS 
(ratio Fe/PS 1:0.025) as carriers, permitted to obtain the higher labelling degrees 
(94,5% of labelling efficiency). 
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Figure 1: Adult neural stem cells isolated from the SVZ of CD1 mice labelled with 
different amounts of SPIOs (0, 100, 200, 400 µg/m Fel) in the presence or absence 
of different transfection agents such as poly-L-Lysine (PLL), polybrene (PB), 
protamine Sulphate (PS) for 24h (A). Prussian blue staining of labelled cells 
permitted to reveal an increase in cell iron content in relation to the amount of 
SPIOs in the cell culture medium and to the presence of transfectants. 400 µg 
Fe/ml with or without tranfectants resulted in cell suffering and aberrant 
morphology. 200 µg Fe/ml in presence of PS for 24 hours, seemed to be the best 
labelling condition (B). 
0 ug Fe 100 ug Fe 200 ug Fe 400 ug Fe 
PLL 
CTRL 
PB 
PS 
 40X 
100X 
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Lower iron concentrations (25-50 µg Fe/ml) were early discarded because of their 
low labelling efficiency. On the contrary, higher iron concentrations (400 µg Fe/ml) 
resulted in evident toxicity and lower cell viability as demonstrated by the figure 1 
and the graph.  
200 µg Fe/ml (Endorem®) in presence of PS has initially been chosen as the best 
labelling condition in term of iron content/cell (110pg Fe/cell), labelled cell rate and 
cell viability. 
 
 
 
 
 
 
 
 
Graph 1. The percentage of Iron-positive cells increased in proportion to the iron 
content in the medium and in the presence of PS (A). In particular we obtained 
94,5%+1 iron-positive cells in the samples incubated with 200 µg Fe/ml for 24h in 
the presence of PS (p<0.001 compared to control). Higher amount of Iron (400 µg 
Fe/ml) enhanced the percentage of labelled cells (A) but strongly decreased the 
viability (P<0.001) (B). Labelling with 100 and 200 µg Fe/ml in the presence of 
different transfection agents (PLL, PB, PS) did not reduce cell viability compared to 
the respective control. The presence of trasfection agents PLL and PB in the 
medium, decreased the percentage of viable cells (P<0.001) whereas the presence 
of PS did not influence cellular viability (B). 
A 
B 
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A higher PS concentration (ratio Fe/PS 1:0.05) was tested in order to further 
increase iron internalization. 
There were no significant differences, in terms of viability and proliferation, 
between mNSCs, incubated for 24h with 200 µg Fe/ml in presence or absence of 
different amount of PS, and non labelled cells (graph 2). 
The percentage of viable cell was 85% for Fe/PS 1:0.025 ratio and 77% for Fe/PS 
1:0.05 ratio compared to the 95% of the control (with no PS). On the contrary, the 
percentage of iron positive cells increased in proportion to the PS content in the 
medium. In particular 94,5% of labelling efficiency was obtained in the samples 
incubated with Fe/PS 1:0.025 ratio and 99% in the samples incubated with Fe/PS 
1:0.05 ratio (graph 2).  
The spectrophotometer analysis revealed an increase of the iron content from 110 
pg Fe/cell to 210 pg Fe/cell increasing PS concentration even if by using the higher 
Fe/PS ratio cell morphology resulted in higher vacuolization (figure 2). In order to 
perform an efficient labelling protocol able to track the cells without perturbing their 
features and functionality, the lower PS concentration has been chosen. 
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Graph 2. Set up of PS concentration. The percentage of Iron-positive cells 
increased in proportion to the PS content in the medium (A). Higher amount of PS 
(Fe/PS 1:0.05 ratio) enhanced the percentage of labelled cells (99%) compared to 
Fe/PS 1:0.025 ratio (94,5%) (P<0.001) (A) and did not significantly influence cell 
viability (B) compared with the respective controls. 
 
 
 
 
 
Figure 2. Set up of PS concentration. Cells incubated with the Fe/PS 1:0.05 ratio 
show a higher iron content per cell compared with Fe/PS 1:0.025 ratio, as 
demonstrated by the blue inclusions visible in optic microscopy after PERL’s 
staining, but the cells appear more vacuolized and with an aberrant morphology. 
 
 
Therefore, kinetic studies were performed by incubating mNSCs with the MNPs for 
different incubation time (24-48-72h) to identify the optimal incubation time needed 
for cell loading. Prussian Blue Staining (Perl’s) demonstrated that the iron 
content/cell increased in proportion to the time of incubation (figure 3, images are 
only representative of the cell iron load, are not objective index of viability, labelling 
    110 pg Fe/cell 
     210 pg Fe/cell 
Fe/PS 1:0.025  Fe/PS 1:0.05 
B 
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efficiency and iron content) and the relassometric results confirmed these data 
(graph 3). 
 
 
 
 
 
Figure 3. PERL’s Staining of incubation studies (100X o.m.). The images displayed 
NSCs incubated with 200 µg Fe/ml and PS for different times (24-28 and 72h). An 
increased iron content per cell was visible in proportion to the incubation time. At 
48 and 72h of incubation, NSCs were characterized by cell vacuolization and an 
aberrant morphology. 
 
 
 
Longer incubation times (48h and 72h), even if increased the iron internalization 
and the iron content per cell, resulted in marked toxicity and aberrant morphology 
as demonstrated by the Perl’s staining (figure 3). Furthermore the labelling 
efficiency did not increase in a statistically significant way.  
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Graph 3. Labelling kinetic studies. The percentage of Iron-positive cells did not 
increase in proportion to the incubation time of NSCs with the labelled medium (A). 
As resulted by the relaxometric assay, T2 decreased in proportion to the incubation 
time (P<0.001) probably due to the increase of iron content per cell(B). 
 
 
 
The 24 hours of incubation appeared to produce an optimal labelling, also in 
relation to viability: as a matter of fact, a time of incubation longer than 24 hours 
resulted in a significant decrease in viability (Data not shown).  
1.2.  Evaluation of labelled NSC features 
After the labelling protocol set up and before proceeding with the in vivo 
experiments, it was demonstrated that labelling NSCs is feasible and does not 
impair cell viability and biological characteristic in vitro. In particular was evaluated 
the maintenance of the phenotypic and functional features such as the 
maintenance of the expression of typical neural stem cell marker, of the self-
renewal capability and the maintenance of the differentiation ability demonstrating 
the inertness of SPIOs and lentiviral infection on neural stem cells. 
1.2.1. Stem cells features maintenance 
Initially, it was analyzed the effect of NSC labelling with SPIOs,   regarding cell 
proliferation capability, by demonstrating the maintenance of the ability to form new 
neurospheres.  
In particular, NSCs washed and replated after the labelling with Endorem® (200 µg 
Fe/ml with PS ratio 1:0.025 for 24h of incubation) maintained the capability to form 
new floating neurospheres, as can be seen in the optical microscopy images 
(figure 4), demonstrating the maintenance of self-renewal capability. In fact, 
neurospheres were visible since 5 days after SPIO-labelled cell replating compared 
to the control non labelled cells. 
B 
*** 
*** 
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Figure 4. Optical Mycroscopy of NSCs. NSCs labelled directly with Endorem® 
maintained the capability to form new neurospheres, as displayed in the figure A 
(after 5 day of culture) if replated soon after labelling, demonstrating their 
maintenance of the self-renewal capability. 
 
 
Furthermore, labelling of NSCs with Endorem® did not affect expression of major 
antigens of immature neural stem cells (such as nestin).  
In fact, as displayed by immune-fluorescence (figure 5), labelled NSCs maintained 
their ability to express nestin (green).  
 
 
 
 
Figure 5. NSCs labelled directly with SPIOs maintained the expression of nestin 
(green), typical neural stem cell marker, as displayed in the figure confirming the 
maintenance of staminality. Nuclei were stained as internal control (DAPI, blue) 
(20X magnification).  
 
 200 µg Fe/ml+PS 
 
20X 
 50 
 
1.2.2. Cell differentiation 
In order to establish if labelling procedures could influence proliferation ability of 
NSCs, the cells were induced to differentiate and successively were analyzed by 
immune-fluorescence for GFAP (marker of astrocytes), Gal-C (marker of 
oligoderocytes) and β-tubulin III (neuronal marker) expression. 
Figure 12 demonstrates that NSCs, replated on matrigel immediately after their 
labelling with SPIOs (200 µg Fe/ml and PS for 24h) and deprived of mitogenic 
factors, maintained their ability to differentiate in neurons (figure 12A), astrocytes 
(figure 12B) and oligodendrocytes (figure 12C). 
Since the labelling efficiency was of 94,5%, the majority of differentiated cells 
contained the iron nanoparticles, as demonstrated by Perl’s staining (figure 12D) of 
the same cells before the differentiation induction, and this confirmed that the 
labelling procedure did not inhibit cell differentiation.  
 
 
 
 
Figure 6. Immune-fluorescence assay on differentiated SPIO-labelled NSCs. 
NSCs replated on matrigel immediatly after their labelling with SPIOs (200 µg 
Fe/ml and PS ratio Fe/PS 1:0,025) for 24h, maintained the ability to differentiate in 
neurons (A) (Anti- β-tubulin III Antibody, green), in astrocytes (B) (anti-GFAP 
Antibody, green) and in oligodendrocytes (C) (Anti-Gal-C Antibody, green). Nuclei 
were counterstained with DAPI (blue). 
The optical image (D), displayed the Perl’s staining of the same labelled NSCs 
before the induction to differentiate (40X o.m.). 
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1.3. In vivo MRI 
Having established a protocol allowing efficient labelling of mNSCs (in terms of 
number of labelled cells and intensity of labelling) using SPIOs without an overall 
short-term or delayed toxicity and functional cell impairment, It was assessed 
whether SPIO-labelled cells could be visualized by MRI after their transplantation 
into animal models of traumatic spinal cord injury.  
For this intent 1,5x105 labelled NSCs were intramedullary injected and followed by 
MRI. Initially two conventional MRI sequences were tested: the spin-echo 
sequences and the gradient-echo sequences. While the spin-echo sequences 
permitted to obtain images for morphological analysis of the site of injury, the 
gradient-echo permitted to enhance the iron signal, with a decreasing on 
morphology definition so, to obtain complete information, all these sequences were 
required. 
Preliminary results, demonstrated the possibility to detect SPIO-labelled NSCs by 
MRI techniques as shown in figure 7. In fact a hypointense signal due to iron 
presence within the injected cells was detectable in the site of injury after their 
intra-medullary injection and the signal was persistent also two months after the 
transplant. 
 
 
 
 
Figure 7. In vivo MR imaging (Spin-Echo, MSME and Gradient-Echo, FLASH, 
sequences) sensibility tests on injured spinal cord mice. The spin-echo sequences 
furnished only morphological informations but were not able to detect the labelled 
cells. SPIO-labelled cells were detectable by the use of gradient-echo sequences, 
7 days after the cell injection into the spinal cord. The yellow arrows identified the 
presence of SPIO-labelled cells. 
 
 
After two months mice were sacrificed and the spinal cords were collected and 
sliced for the histological analysis. Perl’s staining on corresponding serial sagittal 
sections cut from the same spinal cord after the MRI procedure confirmed the 
presence of iron-labelled cells into the site of injury (figure 8). 
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Figure 8. Histological analysis of collected injured spinal cord of positive control 
mice i.s. injected with SPIO labelled cells, after the MRI (Gradient-echo 
sequences). The Prussian blue staining confirmed the presence of SPIO-labelled 
cells into the lesion site. 
 
 
Gradient-echo sequences, therefore was initially used to visualize the fate of NSCs 
after their therapeutic administration (1x106 labelled cells injected) into the tail vein 
for the treatment of traumatic spinal cord injury. 
The figure 9 shows the presence of an hypointense signal into the site of injury 
since day 21 after their injection and the signal was persistent also two month after 
the transplant (not shown). 
 
 
 
Figure 9. In vivo MR imaging (Gradient-Echo, FLASH, sequences) of SPIO-
labelled NSCs injected intravenously in an experimental model of traumatic spinal 
cord injury. Sagittal MRI images of the spinal cord at 21 and 27 days post cell 
injection showed the presence of T2 hyporintense signal in the dorsal portion of the 
spinal cord ( yellow arrows). 
 
After two month mice were sacrificed and the spinal cord was extracted and 
analyzed by ex vivo MRI to confirm that the signal was not due to any artefacts. 
MRI on isolated spinal cord, acquired both in axial and sagittal plan, confirmed the 
presence of typical regions of hypointense signal attributable to SPIO-labelled cells 
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(figure 10), as further demonstrated by Perl’s staining on corresponding serial 
sagittal sections cut from the same spinal cord after the MRI procedure (figure 11). 
 
 
 
 
Figure 10. Ex vivo MR imaging of the injured spinal cord, axial (sx) and sagittal 
(dx) sections. 
 
 
 
 
 
Figure 11. Histological analysis of collected injured spinal cord after the MRI 
(Gradient-echo sequences). The Prussian blue staining confirmed the presence of 
SPIO-labelled cells into the lesion site. 
 
 
For the following in vivo NSC tracking experiments, RARE sequences, strongly 
weighted in T2, were tested in order to obtain an image with a clearly visible iron 
signal in combination with a good morphological resolution. 
The RARE images were demonstrated to be more sensitive in revealing the 
presence of the SPIO-labelled cells. In fact, an hypointense signal was detectable 
since 7 day after the cell administration into the tail vein both in sagittal plan (figure 
12) and coronal plan (figure 13).  
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Figure 12. In vivo MR imaging ( RARE sequences) of SPIO-labelled NSCs injected 
intravenously in experimental model of traumatic spinal cord injury. Sagittal and 
dorsal MRI images of the spinal cord just at 7 days post cell injection showed the 
presence of T2 hyporintense signal in the dorsal portion of the spinal cord (yellow 
circles). 
 
 
 
 
Figure 13. Magnification of an in vivo MR image ( RARE sequences) of the injured 
spinal cord 7 day after labelled cell injection. The sagittal figure on the left showed 
a red grid dividing into 12 axial slices the region containing the hypointense signal. 
The figures on the right showed the most representative axial MR image acquired 
at the level of the slice 12, 6 and 2 respectively. Also coronal images confirmed the 
presence of T2 hypointense signal in the dorsal portion of the spinal cord. 
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After one week mice were sacrificed and the spinal cord was extracted and 
analyzed by ex vivo MRI.  
The presence of typical regions of hypointense signal was revealed also by ex vivo 
MRI on isolated spinal cord, acquired both in axial and sagittal plan, demonstrating 
that the signal was not due to any artefacts (figure 14). 
 
 
Figure 14. Ex vivo MR imaging of the injured spinal cord at one week after the 
SPIO-labelled cells injection, axial (sx) and sagittal (dx) sections. 
 
 
The histological analysis on corresponding serial sagittal sections cut from the 
same spinal cord after the ex vivo MRI procedure, confirmed the presence of 
SPIO-labelled cells in the dorsal portion of the spinal cord (on the left), in proximity 
of the lesion site.  
 
 
 
Figure 15. Histological analysis of collected injured spinal cord after the MRI 
(RARE sequences). The Prussian blue staining confirmed the presence of SPIO-
labelled cells in the dorsal portion of the spinal cord (on the left), into the lesion site  
(20X o.m.). 
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The 40X o.m. permitted to highlight that the labelled cells have emitted some 
protrusions, probably due to their effective differentiation once established to the 
lesion site (figure 16 A). Furthermore a lot of cells are detectable in proximity of 
blood vessels demonstrating their distribution trough the blood flow (figure 16 B). 
 
 
 
 
 
Figure 16. Histological analysis of collected injured spinal cord after the MRI 
(RARE sequences). The 40X o.m. of the Prussian blue stained sections permitted 
to highlight the protrusions emitted by the SPIO-labelled cells localized into the site 
of injury. 
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2. DIRECT LABELLING FOR NUCLEAR IMAGING 
2.1. NSC direct labelling with 111In-oxine 
Since it was difficult to study the early phases of the NSC distribution by MRI, 
mNSC were labelled with 111In-oxine .111Indium is indeed characterized by a γ-
decay that emits two photons, having a 173 and 240 keV energy respectively and a 
half life of 69 hours. Imaging can be performed also 24 and 48 hours after injection, 
with good resolution. The radioisotope is linked with 8-hydrossichinoline (oxine), a 
chelating agent by which it forms a lipophilic complex that is able to penetrate the 
cell membrane. When the complex reaches the cytoplasm, it dissociates, leaving 
111Indium firmly linked to nuclear and cytoplasmic proteins with a stable interaction 
that lasts for more than 24 hours.  
In particular, several incubation time were tested in order to increase the labelling 
efficiency. The cells were initially incubated with 111In-oxine for 15 minutes as 
described by De Vries et al. [70] with 60% of efficiency. A higher incubation time 
was tested in order to further increase the labelling efficiency. Labelling efficiency 
of mNSCs incubated for 30 minutes with 111In-oxine was of 99,4% . 
NSC viability was not affected by the labelling procedures (data not shown).  
Therefore, the final results demonstrated that cell labelling with 111In-oxine can be 
used for in vivo imaging of NSC migration by means of nuclear techniques and by 
exploiting the higher sensitivity of SPET with respect to MRI.  
2.2. In vivo planar SPET imaging 
One million of NSCs were labelled with 60 µCi of 111In-oxine and injected in the tail 
vein of CD1 spinal cord inured mice (for further details about animal models, see 
Materials and Methods, paragraph 1.5.1).  
The pictures were taken with a digital camera separated from the γ-camera and 
were overlaid with the photon emission map. This shrewdness permitted to 
overcome the intrinsic limit of the nuclear based imaging techniques: the lack of 
anatomical information. SPET images fail to localize exactly the source of the 
emitted photon, and indeed the emission map results to be only a bi-dimensional 
projection of a three-dimensional mouse model.  
The image, shown in figure 20, was taken 30 min after injection demonstrates that, 
in the early phases post-injection, stem cells can be detected within the filter 
organs of the animals (lung, liver and kidneys). As a confirmation, acquiring the 
image 1 h later, no more detectable signal was visible in the same area (data not 
shown). 
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Figure 17. Nuclear imaging of NSCs labelled with 111Indium-oxine. Labelled cells 
were visible in the filter organs (lungs, liver and kidneys) 30 minutes after their 
injection into the tail vein. 
 
 
 
The data obtained demonstrated the efficient cell distribution through the blood 
flow (figure 17). Furthermore this technique revealed the great sensitivity of the 
prototypical sensor we used that was provided by the Politecnico of Milan 
(Professor Carlo Fiorini). 
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3. INDIRECT LABELLING FOR BLI 
3.1. Lentiviral production and NSCs infection 
Helper Lentiviral vectors of third generation (pMD2g-VSV-G, pMDLg-RRE and 
pRSV-Rev) useful for the viral production for stem cells infection were offered by 
Dr. Rivella’s Laboratory (Cornell University, New York) and were amplified in DH-
5alpha E.Coli (NEB), purified by an endotoxin free DNA extraction kit (Invitrogen) 
and diluted in TE buffer. 
The pCLL.PGK.Luc.WPRE (PLW) plasmid, containing the Luciferase gene 
controlled by the constitutive promoter PGK, was previously cloned in our 
laboratory (figure 18). 
 
 
 
Figure 18 . Schematic reproduction of the lentiviral vector PLW. 
 
 
 
The lentiviral vectors were produced as described by Tom Dull et al. [132] 
The vector copy number (VCN) viral titer (7,62x105 TU/ml) was calculated on HeLa 
cell lines through the amplification of the lentiviral specific WPRE region from 
genomic DNA of Hela infected cells by the use of the Real-Time PCR technique 
[133] and its comparison to a curve of DNA standards with known VCN. 
NSCs were infected with 5 MOI of PLW lentiviral vectors and polybrene (8 µg/ml) 
and the luciferase expression was evaluated after the cell lysis, by CCD camera 
using a luciferase assay (Promega) and the data obtained, as counts (i.e. photon 
emitted), were normalized on the total protein concentration. Luciferase expression 
obtained was around 4,24x108 counts/mg of protein and the luminescence was 
clearly visible by CCD camera (figure 19).  
 
 
 
 
 
Figure 19. In vitro bioluminescence assay on NSCs infected with 5 MOI of the 
lentiviral vector PLW. 
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3.2. Evaluation of labelled NSC features 
To confirm that lentiviral transduction had not altered the properties of NSCs, 
immune-fluorescence and optical microscopy were performed as previously 
described.  
In particular, NSCs washed and replated after the infection with PLW vector (5 
MOI), maintained the capability to form new floating neurospheres, as shown by 
optical microscopy images (figure 20), demonstrating the maintenance of self-
renewal capability, even if the lentiviral infection with PLW seemed to slow the 
proliferation rate since the neurospheres were visible only 7 days after cell plating 
compared to the 5 days of non infected control cells. This is probably due to the 
integration of PLW DNA in the genome of the NSCs that interfere with the DNA 
replication. 
 
 
 
 
Figure 20. Optical Mycroscopy of NSCs. NSCs labelled indirectly with PLW 
maintain the capability to form new neurospheres, as shown in the figure (after 7 
day of colture) if replated soon after labelling, demonstrating their maintenance of 
the self-renewal capability. 
 
 
Furthermore, labelling of NSCs with PLW did not affect nestin expression (antigens 
of immature neural stem cells).  
In fact, as shown by immune-fluorescence (figure 21), infected NSCs maintained 
their ability to express nestin (green).  
 
 
20X 
PLW infected 
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Figure 21. NSCs infected with PLW vector maintain the expression of nestin 
(green), typical neural stem cell marker, as shown in the figure confirming the 
maintenance of staminality. Nuclei were stained as internal control (DAPI, blue). 
(20X magnification). 
 
3.3. In vivo Bioluminescence imaging (BLI)  
In the research of cell-therapy, the accuracy of transplantation is a fundamental 
premise. In this study the BLI was used as a tool helping the evaluation of the 
transplant success. 
One of the advantages of the BLI is the capability to detect only viable grafted cells 
since the Luciferase reaction is dependent upon oxygen and ATP, furthermore the 
BLI permits to obtain data easily and faster compared to other imaging techniques 
such as MRI. One of the limits of BLI is its lower anatomical resolution. 
To examine the engrafted cells viability once arrived in the lesion site, 1×106 of 
infected NSCs were injected into the tail vein of CD1 spinal cord injured mice.  
The accuracy of transplantation was confirmed immediately after transplantation 
using BLI. The day after the cell transplantation, D-luciferine was intraperitoneally 
administrated (80 mg/kg body weight). Five minutes after D-luciferin injection, 
images acquisition started (Xenogen-IVIS Lumina). In the set up experiments, 
serial images were acquired from 5 to 35 min after D-luciferin administration in 
order to study the kinetic of distribution and metabolism of the luciferine. The 
luminescence peak was found between 15 and 25 minutes after D-luciferin 
injection (data not shown). So this time was chosen as for animal acquisition.  
Mice injected with lentivirally infected mNSCs were acquired every day, for the first 
week after the transplant and then once a week for a month.  
NSCs, infected with the viral vector PLW, and intramedullary injected, produced a 
very high signal localized in the site of injection. On the other hand, intravenously 
injected cells were detectable since one week after the transplant within the lesion 
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of injured mice (figure 22) demonstrating the presence of viable cells and 
confirming MRI data, furthermore the signal was detectable also 6 weeks after the 
transplant demonstrating cell survival into the lesion site. 
 
 
 
  
 
Figure 22. In vivo bioluminescence image of NSCs infected with 
pCLL.PGK.Luc.WPRE (PLW) vector. 1x106 infected cells were injected into the tail 
vein of injured mice (figure on the right). All the mice, used as internal positive 
controls, were stereotactically injected, with 1,5x105 infected cells, directly into the 
injured spinal cord (figure on the left). Luciferase activity was detectable in the 
lesion site, 1 week after their injection into the tail vein. 
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Cell-based therapy has been announced as being a promising, novel therapeutic 
strategy for recovery from various diseases. In particular, two big branches can be 
identified: the stem cell-mediated therapy and the immunotherapy.  
The use of stem cells in cell-mediated therapy is of considerable interest for 
studying the regeneration and reconstitution of tissues in damages caused by 
trauma as well as in inflammatory and degenerative diseases.  
More in particular, NSC-based therapeutic approaches have recently become the 
subject of study due to their huge potential for application in both cell-based and 
gene therapy of CNS disorders. 
These cells, originated from the SVZ of CD1 mice, are able to differentiate into 
many neuronal cell types in vitro, such as neurons, astrocytes an oligodendrocytes 
and to restore structure and function of the nervous system in diseased animal 
models. 
Preliminary data obtained with this type of treatment have demonstrated its efficacy 
as proved by motor recovery assessed by motor behavioural test. 
Once the efficacy and safety of these novel therapeutic approaches will be fully 
demonstrated in preclinical models of CNS disorders, they will rapidly move 
towards clinical testing. Furthermore, controversial, issues remain unresolved with 
respect to the molecular mechanisms underlying cell mediated treatments. To this 
purpose, molecular and cellular imaging retains a fundamental role not only in 
preclinical studies, but also in clinical practice, since the possibility to accurately 
evaluate at the early stage of the treatment the precise delivery and/or homing of 
cells to target tissues is crucial for the clinical success of such applications.  
Indeed, non-invasive, imaging-based methods have been recently developed to in 
vivo follow transplanted cells that had been previously labelled with different 
protocols. These imaging techniques allow to track the localization, distribution and 
migration of administered cells once introduced into the living model. The ability to 
track the location of cells will allow several questions to be answered: 1) if injected 
through the vein, where do these cells go? 2) if implanted, do cells remain in the 
site of implantation or do they migrate to the target tissue? 3) once arrived to the 
target organ or tissue, how do they interact with their microenvironment or with the 
resident cells? 4) how long can injected cells survive? 5) can transplanted cells 
differentiate into the desired tissues?  
Furthermore, the use of imaging techniques permits to introduce early and 
intermediate check points of cell-mediated treatment efficacy being previously 
evaluated only by the final functional recovery and provides direct and clear 
parameters able to depict cell behavior after injection.  
In general, successful in vivo imaging requires a cell to be labelled, so as to 
provide sufficient contrast for detection by imaging instruments. Cell labelling can 
be performed by following two different strategies: direct and indirect protocols. The 
direct labelling methodology is based on the use of contrast agents, such as 
paramagnetic nanoparticles and fluorescent or radioactive molecules that a-
specifically enter the cell membrane and label cells, while the indirect strategy 
exploits the genetic engineering of cells through introducing reporter genes coding 
for reporter proteins within the host genome. The use of contrast agents permits to 
label the cells easily, and so to perform different types of imaging. The imaging 
modalities available are indeed very different from each other in terms of spatial 
resolution, sensitivity, type of information provided (anatomical or functional 
information), depth of tissue penetration and the type and amount of required 
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probe. For these reasons, very often a multimodal approach is needed to 
overcome the intrinsic limitations of each single imaging technique and provide 
more informative data. 
Our studies demonstrated that direct labelling procedures with paramagnetic 
nanoparticles of NSCs is efficient and safe. In particular, we used SPIOs 
(Endorem®) as a contrast agents and protamine sulphate (PS), being both FDA 
approved for clinical use. Dose-response and incubation time studies were 
performed so that the specific optimal dose and time of incubation should be 
identified. In particular, for NSCs, the best labelling condition is the incubation with 
200 µg of iron/ml of culture medium for 24 hours in presence of PS (ratio Fe/PS 
1:0,025) . 
Once the best labelling protocols were identified, we demonstrated that after the 
labelling, there was no alteration of the NSC phenotype or its behaviour in different 
conditions and that an intracellular iron level of 110 pg/cell resulted to be able to 
produce a good signal in MRI. 
Another problem in the setting up of a cell imaging protocol is the need to visualize 
even small amounts of cells in the target organ. Our data demonstrated that MRI 
was able to show NSC accumulation within the target tissue with a good sensitivity 
even if MRI technique for its complexity and the long time of acquisition do not 
permit to follow early phases distribution. Furthermore MRI needed an expert 
technician for images acquiring and reading.  
A partial solution to this problem can be found by using a-specific long term labels 
such as radionuclides, whose half life were consistent with the cell cycle duration 
and with the kinetic of the process to be studied in order to have enough time to 
reveal the desired check point. This is the case of the NSCs labelled with 111In-
Oxine that, having a half time of 69 hours, permits to follow early phase distribution 
from the site of injection. 
Nuclear imaging demonstrated that the prototypical sensor (provided by the 
Politecnico of Milan, Professor Carlo Fiorini) has a good sensitivity: it is able to 
image circulating NSCs, even though only in a bi-dimensional perspective, and to 
integrate the information deriving from MRI studies, so that the combination of MRI 
and scintigraphy permits to merge the special high resolution of MRI with the high 
sensitivity and the whole body images of scintigraphy thus allowing to partially 
overcome the disadvantages of each single technique. 
As far as it is concerned, NSC imaging by MRI provided good anatomical 
information that permitted to localize accurately the presence of iron, due to 
injected NSC within the spinal cord. 
The setting up of an imaging protocol to visualize proliferating cells has to take into 
account the dilution of the label through cell generations occurring in direct 
labelling strategies and the fast decay of radioactive signal that limits the possibility 
to track cells to short periods of time. The unique global solution to this problem is 
the use of reporter genes for the engineering of the cells that have to be studied in 
vivo in order to pass the biomarker, reporter protein, from a cell unaltered over time 
to the cell litters. 
In our study, NSCs were engineered to express the reporter gene luciferase under 
the control of a constitutive promoter (PGK). The great advantages of the BLI is 
that permits to acquire only viable cells because the reaction needs of oxygens and 
ATP, provides informations for long times only requiring the addiction of the 
substrate of the enzyme (luciferine) and lacks background noise. 
 66 
 
Furthermore our data demonstrated the feasibility and sensitivity of BLI in revealing 
luminescent cell accumulation even if this technique lacks of anatomical resolution 
and the labelling process is quite elaborated.  
Furthermore cell engineering is not always possible because of the danger in 
producing cell genetic modifications or because of the possibility to evoke an 
immune response against the reporter protein when this is reintroduced into the 
living model. 
In this context, indirect cell labelling provide the means for the long term study of 
parameters describing the efficacy of a cell-mediated treatment permitting the 
identification of important early intermediate points fundamental for the estimation 
of treatment efficacy that can be studied easier with direct labelling strategies. The 
identification and the exploiting of these intermediate points could change also the 
clinical approach in the evaluation of treatment efficacy not basing only on the final 
long term recovery of function or tumour shrinkage but to the in vivo study of their 
molecular and cellular bases. In this scenario, the treatment scheduling could 
potentially be improved, making it possible to keep each phase of the treatment 
under observation. 
 
The data reported in this thesis permit us to validate our labelling protocols as 
efficient strategies to follow in vivo the cells that are systemically administered to 
mouse models. They thus demonstrate the value of our models for the in vivo study 
of important variables for the evaluation of the efficacy of a cell-mediated therapy: 
first of all the cell ability to in vivo migrate and localize into the target, that is the first 
step of an efficient therapeutic protocol. 
However, to evaluate the cell-mediated treatment efficacy it is necessary to 
perform further experiments in order to correlate the in vivo evaluated cell 
localization and differentiation with the restoration of spinal cord injury.  
Furthermore all data obtained by imaging methods will be compared and correlated 
with data on motor recovery by different behavioural tests (BMS scale). 
The route of administration, the scheduling of treatment and the potential use of 
adjuvant pharmacological treatments will be evaluated. Genetic engineering of 
NSCs will be carried out to make them able to express a reporter gene (Luciferase 
or Katushka) under control of a neuron specific promoter- to in vivo visualize their 
neuronal differentiation.  
The anatomical information provided by MRI will permit to have a global view of the 
system and will thus allow the evaluation of specific parameters linked to the cell-
mediated treatment as the spinal cord morphology, and will at the same time 
highlight the cell population in study and its effect on the organism. 
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1. PRINCIPLES OF NMR 
Nuclear Magnetic Resonance (NMR) deals with the interaction between an 
oscillating magnetic field and the net magnetization of a sample, which originates 
from its constituent nuclei in the presence of a static magnetic field . 
The nuclei at the centre of atoms are electrically charged for the presence of 
protons. In addition to this property many, but not all, atomic nuclei (isotopes or 
nuclides) possess an angular momentum or spin I (figure 1), which is caused by 
the rotation of nucleus about its axis. 
 
 
 
Figure 1: representation of an atomic nucleus having a nuclear spin 
 
Principally, the nuclear spin follows the rules of quantum mechanics. A rotating 
charge (circular current) induces a magnetic dipole (µ) (Figure 1); thus, all atomic 
nuclei with spin I behave as tiny compass needles. As long as no external 
magnetic fields exist these "compass needles" are statistically oriented in all 
possible spatial directions (figure 2a).  
 
MagnetizationB0a) b)
 
 
Figure 2: orientation of the nuclear magnetic dipole moment. 
 
However, if we subject a substance to a magnetic field (B0), the magnetic dipoles 
strive to align themselves along the direction of the magnetic field, and the 
magnetization precesses along a conical path around the B0 field direction (figure 
2b). According to quantum mechanics, an angular momentum can have only a 
restricted number of alignments with respect to the magnetic field. Hence, the 
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angular momentum of, for example, the hydrogen nucleus (proton, 1H), which has 
spin I = 1/2, can have only two (2I + 1) possible stable orientations relative to the 
magnetic field B0: one parallel to the magnetic field, the other anti-parallel to it 
(figure 3).  
 
 
 
Figure 3: Representation of energy level differences during spin alignment and  
representation of the build-up of macroscopic magnetization Mz of a sample 
 
The two spin states differ in their energy (figure 3) so that the probability of finding 
a spin in a certain state is not uniform. A parallel orientation obviously means less 
energy than an antiparallel direction. The difference in energy ∆E (Figure 3) is 
proportional to the field strength B0: this means that doubling the field strength 
entails a doubling of energy difference . There is in addition a temperature effect: at 
absolute zero all the nuclear spins are aligned along the field direction, whereas at 
room temperature the thermal energy works against alignment, i.e. temperature 
interferes with an ordered arrangement. As a result, the two energy levels are not 
equally populated and there is a slight predominance of vectors in the parallel 
configuration, according to the Boltzmann’s law distribution. At a typical magnetic 
field strength at room temperature and in thermal equilibrium, for every one million 
nuclei at the higher energy level one million and six nuclei would exist at the lower 
energy level. Consequently, a macroscopic magnetization Mz in the magnetic field 
results as the sum of all microscopic nuclear magnetic dipole moments (Figure 3) 
and this magnetization can be detected. The net magnetization lies along the axis 
of the main magnetic field (in general defined as the z-axis) and is named 
“Longitudinal Magnetization”.  
The nuclei of atoms placed in a magnetic field are not exactly aligned along the 
direction of the lines of force of the field: the magnetic axis of each nucleus tends to 
be disposed in an oscillating way along the vector of field itself, as with the needle 
of the compass. This oscillation combines with the motion of spin, giving rise to a 
complex movement of rotation on a conical surface (Figure 4) having its axis along 
the direction of stable magnetic field. This movement is called precession of the 
nuclei, and is similar to the motion of a gyroscope that oscillates on its axis of 
rotation due to the gravity field of the earth. The speed of precession is proportional 
to the magnetic field strength and is different for each atom. The precession rate is 
called Larmor frequency, and, for hydrogen nucleus, is in the range of 
radiofrequencies (figure 4).  
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Figure 4: schematic representation of precession movement  
and value of Larmor frequency for different intensity of B0 
 
If we irradiate the sample with radio waves (in the MHz frequency range) the proton 
will absorb the energy and be promoted to the less favourable higher energy state 
and the precession rate of all nucleus is in the same position of conic surface. This 
energy absorption is called resonance because the frequency of the applied 
radiation and the precession coincide or resonate. 
The resulting effect of the nucleus in phase concordance is the formation of a new 
magnetization vector along the xy plane (perpendicular to B0 vector), named 
Transverse Magnetization (figure 5a). 
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Figure 5: relative position of longitudinal and transverse magnetization 
 in presence a) or absence b) of a radiofrequency. 
 
When radiofrequency pulse is removed, nuclei start losing their stored energy, 
generating radiofrequency waves that can be detected. During this phenomenon, 
the net magnetization from the xy plane will rotate back until it is aligned again with 
B0 (full recovery of longitudinal magnetization)(Figure 5b). At the same time all 
spins will spread out and loose coherence with each other and the x-y component 
of the magnetization will gradually disappear. 
The recovery of longitudinal magnetization occurs with a time constant T1, referred 
to as T1 o spin lattice relaxation time: the energy is just handed over to their 
surroundings, the so-called lattice. The gradual loss of transversal magnetization 
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occurs with a time constant T2, referred to as T2 or spin-spin relaxation time Each 
nucleus in fact is influenced by the small magnetic fields from neighbouring nuclei, 
which are somehow characteristics for a tissue. Since the nuclear spin relaxation 
processes depend on the existence of molecular motions to generate a randomly 
varying magnetic field, we can get valuable information about these motions, and 
therefore about the type of tissue, from the relaxation rates. 
1.1.  Contrast agents 
Magnetic relaxation can be enhanced using contrast agents. In fact spin-lattice 
relaxation T1 and spin-spin relaxation T2 may be shortened considerably in 
presence of paramagnetic species. The resulting effect is a change in the MR 
signal.  
Magnetism is a fundamental property of matter. Substances are divided in three 
classes, according to their magnetic properties: diamagnetic, paramagnetic, and 
ferromagnetic. Diamagnetic substances do not exhibit magnetic properties 
Paramagnetic species instead, do not exhibit magnetic properties outside a 
magnetic field, but when placed in a magnetic field exhibit a slight positive 
interaction with it. . Paramagnetic species do not retain any magnetization in the 
absence of an externally applied magnetic field and this is the difference with the 
ferromagnetic substances 
Paramagnetic species are used to generate contrast in NMR and MRI. They have 
unpaired electrons with associated magnetic fields which are approximately one 
thousand times stronger than those corresponding to water protons. Such 
substances therefore interact with water protons exactly as surrounding protons but 
with much stronger magnetic fields, causing a stronger impact on their relaxation 
rates. 
Some examples are molecular oxygen, stable radicals (i.e. nitroxide radical) or 
metal ion (i.e. many transition metal ions).  
Radicals generally cause damage to the living tissues. Therefore, they are not 
suitable candidates for medical MRI purposes. The paramagnetic effect of oxygen, 
although demonstrable, seems too weak for practical applications. Paramagnetic 
metal ions do show suitable effect which depends on their number of unpaired 
electrons.  
There are many transition and lanthanide metals with unpaired electrons , but for 
the metal to be effective as a relaxation agent, their electron spin-relaxation time 
must match the Larmor frequency of the protons. This condition is best met for the 
Fe3+, Mn2+ and Gd3+ ions.  
The main problem with this paramagnetic heavy metal ions is that in their native 
form they are toxic. Research is focused on the development of stable 
paramagnetic ion complexes. Both the metal ion and the ligand usually exhibit 
substantial toxicity in the unbound state: together, however, they may create a 
thermodynamically and kinetically stable compound which is well tolerated. 
Gadolinium (Gd) is the paramagnetic substance most commonly used as MR 
contrast agent. It is chelated to DTPA (Gd-DTPA) to solve toxicity problems. 
A relatively new type of paramagnetic contrast agents are the so-called 
superparamagnetic iron oxide (SPIO) based colloids. They consist of non-
stoichiometric microcrystalline magnetite cores which are coated with dextranes (in 
ferumoxide) or siloxanes (in ferumoxils). Commercially available iron oxide contrast 
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agents include Endorem®, Feridex IV® and Sinerem®. The compositions and 
physicochemical properties of non-stoichiometric magnetite are continuously 
variated between those of Fe3O4 and Fe2O3. Conceptually, these cation-deficient, 
inverse-spinel phases are formed by partial oxidation of Fe(II) in stoichiometric 
magnetite. 
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2. PRINCIPLES OF RELASSOMETRY 
Relaxometry is an instrument able to acquire the NMR (nuclear magnetic 
resonance) signal produced by nuclei of test samples. It is formed by a circular coil 
capable of generating a uniform magnetic field, a generator, a receveir of, 
respectively, radiofrequency (RF) pulse and output, and a computer for processing 
signals received (figure 1). 
 
 
 
Figure 1: Block diagram of an NMR system 
 
To obtain measures "weighed" in a selective manner according to the time T1 
(recovery of longitudinal magnetisation) or T2 (loss of transversal magnetization), it 
is essential to use specific sequences of nuclear excitation and collection of 
signals: by varying the types of acquisition and/or regulatory factors of the 
sequences will be possible to have images with desired weighing.  
The most common sequence is the sequence Spin-Echo (SE), which allows to get 
values weighed in T2 without the interference of the inhomogeneities of the 
magnetic field. This sequence is also highly flexible and, by varying some 
parameters of its acquisition, it is possible to obtain also measures in T1 weighted 
and proton density.  
The sequence Spin-Echo was now here described in detail.  
The transverse magnetization is sensitive to the intrinsic inhomogeneities which 
are inevitably present in any magnetic field: they would lead to a false interpretation 
of results, because they determine an apparent more rapid decay of T2, due to the 
spontaneous dephasing of nuclei of atoms excited. To eliminate this problem, the 
rephasing signal of nuclear spin after an RT pulse at 180° (respect to magnetic 
field) was recording with Spin Echo sequence.  
In practice, each SE sequence is composed of an initial pulse at 90° which aim is 
to bring the magnetization on the transverse plane. At this point, the spin direction 
of the protons begins to de-phase of on the basis either of their T2 and nor of the 
inhomogeneities of the magnetic field: if the signal was measured at this time, you 
collect a FID signal (Free Induction Decay, namely the spontaneous fall of the 
magnetization in the absence of other pulses) (figure 2).  
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Figure 2: RT pulse with decaying NMR signal 
 
Then a pulse at 180° was applied: note that, since the magnetization vector is 
currently on the transverse plane, this impulse at 180° has the effect to " flip" the 
orientation of the spin direction. In this way, after a time equal to twice the time 
elapsed between the pulse at 90° and 180°, the precession of the nuclei back into 
phase and the transverse magnetization takes a maximum value that is measured 
by the instrument (in fact with the application of a 180° pulse, this fanning-out is at 
least partially inverted so that phase coherence is again established for a short 
time and a "spin-echo" signal can be obtained). 
If a whole series of 180° pulses are applied, it results in a continuous rephasing of 
the nuclei in the opposite direction, with production of a succession of spin-echoes, 
and because no energy is added at the system, each registration of signal T2 is 
worth less and less, and this way permitted the record of the fall of the transverse 
magnetization (the phase relationship at time 2t1 gradually disappears again 
producing a signal which looks like a FID) (figure 3). This sequence, comprising 
one 90° pulse followed by a series of 180° pulses, is termed a "Carr-Purcell 
sequence". 
 
 
 
Figure 3: Carr Purcell Sequence for the determination of the transverse relaxation 
time T2 
 
The SE sequence is characterized by three fundamental parameters that must be 
programmed by the operator, and whose values determine the characteristics of 
the final images. First, the repetition time of pulse at 180° (namely number of 
points, represents a discretisation of the total time of measurement), that is the 
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parameter which decides the length of the sequence and the start of a subsequent 
phase of acquisition. Secondly, the interval between pulse at 90° to 180° 
determines the time to echo (pi), which is equal to twice this value, since half the 
time is spent to allow the de-phasing of the precession of protons (interval between 
pulse at 90° and 180°) and the other half, just the same, spends between 180° 
pulse and collection of eco of spin resulting by rephasing. Finally, the presence of a 
possible repetition pulse at 180° within a given sequence is determined by the 
echo number. This repetition allows the collection of late echoes, useful for 
evaluating the signal deriving from sample test characterized by long T2. 
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3. PRINCIPLES OF MRI 
When NMR is used for imaging, we refer to Magnetic Resonance Imaging (MRI). 
Hydrogen is by far the most commonly observed nucleus in MRI, because of its 
favourable magnetic properties and its abundance. 1H-MR images reflect the 
density of hydrogen, main component in tissues as water or fat. To be more 
precise , MR signal intensity reflects the number of MR-visible protons in a unit 
volume of tissue; in other words it reflects the density of mobile hydrogen nuclei 
influenced by their chemical environment, which causes magnetic relaxation times, 
T1 and T2, to occur (see appendix 2 for details about the physical basis of MR 
signal). 
Principal components of an MR imaging system are : the main magnet, that 
generate the magnetic field and polarizes the sample, the magnetic field gradients, 
for spatial reconstruction and localization of signal, and the radiofrequency coils to 
transmit and/or receive the MR imaging signal (figure 1). The whole system is 
controlled by one or more computer and associated signal processing equipment.  
 
 
 
Figure 1: Schematic representation of MRI components. 
 
The magnet 
The magnet is the largest and most expensive component of the scanner, and its 
strength is measured in Tesla (T). Clinical magnets generally have a field strength 
in the range 0.1—3.0 T, with research systems available up to 9.4 T for human use 
and 21 T for animal systems. The homogeneity of the basic magnetic field over the 
examination volume should be as high as possible to ensure low image distortion 
and high signal homogeneity (high potential signal to noise ratio for good image 
quality). Besides, the homogenous examination volume should be as large as 
possible. A cylindrical main magnet with the homogeneous volume centred on the 
central axis fulfils all these requirements and, therefore, represents the most 
frequent magnet design today, and in general it is based on the use of 
superconducting electromagnet.  
When a niobium-titanium or niobium-tin alloy is cooled by liquid helium to −269°C it 
becomes a superconductor, losing resistance to the flow of electrical current and 
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can have extremely high field strengths, with very high stability. The construction of 
such magnets is extremely costly, and the cryogenic helium is expensive and 
difficult to handle. However, despite their cost, helium cooled superconducting 
magnets are the most common type found in MRI scanners today. 
Most superconducting magnets have their coils of superconductive wire immersed 
in liquid helium, inside a vessel called a cryostat. Despite thermal insulation, 
ambient heat causes the helium to slowly boil off. Such magnets, therefore, require 
regular topping-up with liquid helium. Generally a cryocooler, also known as a 
coldhead, is used to condense some helium vapour back into the liquid helium 
bath. Several manufacturers now offer 'cryogenless' scanners, where instead of 
being immersed in liquid helium the magnet wire is cooled directly by a cryocooler. 
When a sample is placed into the scanner, it creates the inhomogeneities in the 
field, causing region showing no signal and spatial distortion in the acquired 
images. To restore the field homogeneity, a set of shim coils are included in the 
scanner. These are resistive coils, usually at room temperature, capable to 
produce secondary magnetic fields which correct inhomogeneities and errors in the 
magnetic field strength. This process of “shimming” is usually automated. 
 
The gradient system 
The magnetic field gradients give rise to linear variations of magnetic field strength. 
In fact, gradient coils are used to spatially encode the positions of protons by 
varying the magnetic field linearly across the imaging volume.  
In order to produce an image, 3 gradients in 3 orthogonal orientations are used: 
one gradient is used to “locate” the level of each plane and is known as “slice 
gradient”; the other two gradients are used to locate points within each plane. They 
are called “frequency” and “phase encoding” gradients. 
Gradient coils are usually resistive electromagnets powered by sophisticated 
amplifiers which permit rapid and precise adjustments of field strength and 
direction. 
Scan speed depends on the gradient system performance, and the optimal system 
must be able to cover large examination volume in the shortest possible time. In 
general, the gradient system requirements can be best met with a cylindrical 
design that fits magnet geometry. 
 
The Radiofrequency system 
The radiofrequency (RF) system consists of a RF transmit coil, positioned inside 
the magnet, for selective RF excitation of the spins and a RF receiver coil system 
for picking up the weak RF signal resulting from excited nuclei (figure 2).  
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1. The magnetic field 
is used to align
hydrogen protons
in the body
2. Radio frequency waves 
are absorbed by the
protons and then 
emitted as a signal.
3. A radio frequency coil 
picks up the signal
and transmits it to 
the computer.
4. The computer 
processes the data
and an image is
generated
 
 
Figure 2: representation of Radiofrequency system. 
 
Often both transmit and receive functions are performed by the same coil; 
nevertheless in some systems, it is advantageous to employ separate transmit and 
receiver coils. In general, the radio frequency (RF) transmission system consists of 
an RF synthesizer, a power amplifier and a transmitting coil, whereas the receiver 
consists of the coil, a pre-amplifier and a signal processing system.  
Radiofrequency coils can be constructed with a variety of geometries and they are 
increasingly built for specific applications; however, large cylindrical volume 
transmit RF coils with a conductor geometry similar to a birdcage are typically 
used. 
 
Image formation 
The radiofrequency signal picked up by the receiver at the end of an acquisition 
doesn’t have an intrinsic spatial information: it is not able to discriminate signal 
deriving from different points of the sample, and cannot be used to reconstruct an 
image. The passage between raw signal and image formation is based on a 
process of spatial codification, with attribution of a specific frequency and 
resonance phase for each point of the space: this is possible thanks to the 
application of the gradients (see paragraph above).  
This way, at each different point of the examined space, identified through a 
frequency and phase codification, is assigned a numeric value of intensity that is 
translated in a different intensity of grey scale on the image. 
One of the big advantages of MRI over other imaging techniques is its ability to 
image non-invasively slices of an object at any arbitrary position, thickness and 
orientation. This is obtained by applying an RF pulse with a range of frequencies 
together with a slice magnetic field in the proper orientation. This range of 
frequencies associated with the RF pulse is referred to as the “bandwidth” and 
directly determines the slice thickness. Slice thickness can also be altered by 
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changing the slope of the gradient (a very strong gradient allows the reading of 
thinner slices, and vice versa).  
 An MR image is essentially a two-dimensional representation of the intensity of the 
magnetic properties of the observed nucleus as a function of its distribution in 
space.  
Many factors affect signal intensity and contrast of an MR image. They include 
intrinsic factors like proton density, T1 and T2 relaxation times and diffusion, as 
well as extrinsic or experimental factors, such as parameters of acquisition. 
One of the biggest advantages of MRI is that image contrast can be optimized for 
specific purposes and the choice of pulse sequences determines the weighting and 
the quality of the images. A multitude of sequences are available in MRI through 
conventional (Spin Echo and Gradient Echo sequences), fast imaging and ultra 
fast imaging. 
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4.  PRINCIPLES OF SPECT 
SPECT (Single Photon Emission Computed Tomography) tomograph is a device 
able to detect high energy photons emitted from the subject under examination, 
following the administration, generally by intravenous injection, of radioactively 
labelled tracers. After reaching the target organ, the tracers are retained there as a 
result of transport, binding to receptors and antigens, reaction with enzymes, 
biochemical and mechanical trapping, phagocytosis, or a combination of the 
above.  
The labelled tracers contain an excited nucleus -as a radionuclide- which is 
unstable and can spontaneously stabilize to a less-excited system. The resulting 
transformation alters the structure of the nucleus and causes the emission of either 
a photon or a high-velocity particle with a mass (such as an electron, alpha particle, 
or other type). The radioactive decay is a random process on the atomic level, in 
that it is impossible to predict when a given atom will decay, but given a large 
number of similar atoms the decay rate, on average, is predictable, and can be 
used to image a specific process or cells. One of the main advantages of the 
nuclear imaging techniques is their very high sensitivity, when compared with other 
in-vivo imaging techniques. 
SPECT is based on the use of radiotracers labelled with a radionuclide, such as 
99mTc, 123I, 125I, 111In and 201Tl, that decays with emission of single photons with 
different energy (e.g., 111In has two emission lines at 171 and 245 keV, 99mTc has a 
single line at 140 keV). To locate the source of an emitted photon, its direction of 
incidence into the detection system needs to be accurately selected and its 
position of interaction determined in the position sensitive detector. 
Principal components that comprise a SPECT imaging system include: the 
collimator, a scintillation crystal, the position sensitive photo-detector, which is 
traditionally based on photomultiplier tubes, and the readout electronic, which is 
dependent on the type of photo-detector used and gives information about the 
position of interaction and the energy of each detected gamma photon (figure 1). 
 
 
γ rays
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Amplifiers
Position
decoding
circuits
γ signal γ signal
 
 
Figure 1: schematic representation of a gamma camera. 
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The collimator is a device made of a high-Z material such as lead, which selects 
gamma rays along particular directions in order to form an image on the sensitive 
area of the gamma-camera. There are different options for the collimator geometry, 
among which one of the most commonly used is the parallel holes. In this case, the 
holes of the collimator are parallel and permit the passage only of the photons 
perpendicular to the surface of the photodetector. The image obtained is thus the 
projection of the distribution of the radio tracer inside the patient on a plane parallel 
to the scintillator crystal or the photo-detector. This kind of collimator is also the 
one which has been used during the measurements with the Hi-Cam Gamma 
Camera prototype (see next paragraph). 
The scintillation crystal is the fundamental constituent of a gamma camera: its 
function is to convert the high energy gamma photons into many lower energy 
photons, usually in the visible range, which can easily be detected by the photo-
detector. On the contrary, without a scintillator, the photo-detector would be almost 
transparent to the gamma radiation and wouldn’t provide any useful signals.  
The gamma photon, leaving the patient and impinging on the scintillator, is called 
the primary photon. When it interacts with the scintillator, it leaves part or all of his 
energy inside the crystal and, with part of the lost energy, a certain number of lower 
energy photons, called secondary photons, are generated. The energy spectrum of 
the secondary photons generated is usually composed of one or two close lines, 
which depend on the scintillator used. This means that, at a first degree of 
approximation we can consider that all the secondary photons have the same 
energy. Due to the conservation of energy and the fact that the secondary photons 
have the same energy, the number of secondary photons is proportional to the 
amount of energy lost inside the scintillator by the primary photon. For example, if 
we consider only the events in which the primary photon has released all of his 
energy inside the crystal, i.e. the photopeak in the energy spectrum, the number of 
secondary photons is proportional to the energy of the photon emitted by the radio-
tracer. 
The way the primary photon looses energy inside the crystal can be described in 
short as follows: when the gamma photon leaves the patient, it knocks the crystal 
and loses energy, determining the production of a high energy ionizing electron 
(figure 2).  
 
inside the detector crystal
path of the electron
through the crystal 
lattice
atom in the crystal latticelight photons
electron (from Compton scattering 
or the photoelectric effect)
 
 
Figure 2: events that happened inside the crystal. 
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The generated electron loses its kinetic energy in the form of thermal energy, light 
photons or by ionizing other electrons, which again will loose their energy inside 
the crystal through the same mechanisms, until all the electrons find a minimal 
energy state. At the end of the process part of the energy of the primary photon is 
converted into many secondary photons, while the rest of the energy is “lost” in 
non-radiative transitions, which convert it in thermal energy inside the crystal. 
At the energies relevant for the SPECT there are two ways the primary photon can 
make the first interaction with the scintillator: the photoelectric effect and the 
Compton effect (see figure 3). In the first case, all the energy of the gamma photon 
is lost inside the crystal, generating the photopeak in the energy spectrum, while in 
the second case only part of the energy remains inside the crystal, because the 
rest is taken away by the deviated gamma photon.  
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incident 
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1. expulsions 
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of a free orbital 3. emissions 
of a photon
expulsed electron
(=photo-electron)
 
 
Figure 3: graphic representation of Compton effect (left panel) and photoelectric 
effect (right panel). 
 
 
There are many different kinds of scintillators, but the most common in the gamma 
cameras are the inorganic scintillators. They are high-Z crystals, so that they have 
a high stopping power for the primary photons, and are transparent to the visible 
light, in order to let the secondary photons reach the photo-detector. The most 
important figures of Merit of the scintillator are usually considered the light yield, i.e. 
the total number of secondary photons generated per unit energy deposited inside 
the crystal, the stopping power for high energy photons and the decay time 
constant, i.e. the time in which the secondary photons are generated, after the 
detection of the primary photon. Being one of the most important parts of the 
gamma cameras, a big amount of research has been done in order to optimize the 
parameters of the scintillator, so that nowadays many kinds of inorganic 
scintillators are available. The most common are NaI(Tl), CsI(Tl), used for Hi-Cam 
prototype (see next paragraph), or, more recently, LaBr3(Ce). 
The secondary photons are detected by the photo-detector, which is placed at the 
opposite side of the scintillator, with respect to the collimator. Its function is to 
convert the secondary photons into a proportional electronic signal. One very 
common photo-detector, for these application, is the photomultiplier tube, or PMT. 
Inside the photomultiplier, there is a photocathode, which absorbs the visible 
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photons generating free electrons, that are subsequently accelerated in a vacuum 
tube by a sequence of dynodes, having a positive potential increasing 
proportionally to the distance from photocathode. Along their path inside the tube, 
the interaction of the electrons with dynodes determines the formation of new 
electrons, obtaining a signal amplification. At the and of the tube there is the 
anode, which collects all the electrons and generates an electric signal whose 
amplitude is proportional to the number of secondary photons interacting at the 
photocatode and thus also to the total energy released in the scintillator by the 
gamma photon.  
With respect to the simplifies structure described above, some modification have 
been implemented, in order to add position sensitivity to certain types of PMTs and 
actually record the image generated by the collimator. 
 
 
photocathode dynodes anodes
 
 
Figure 4: schematic representation of a photomultiplier. 
 
 
More recently, different photo-detectors, based on solid-state silicon devices, have 
been proposed in order to improve performances of the gamma cameras. In 
particular, the aim of the use of silicon devices is to get better energy performance, 
spatial resolution, more compactness, lower cost and less sensitivity to magnetic 
fields, with respect to PMTs, which could allow their use in integration with MRI. All 
these solution, however, are under research and the widespread photo-detector for 
gamma cameras remains the PMT. For example, the Hi-Cam gamma camera is a 
research project for evaluating the use of a very peculiar type of silicon detector, 
the Silicon Drift Detector (SDD), as the photo-detector in a high resolution gamma 
camera. 
In origin the SPECT was used only for human studies, but recently it has been 
rescaled for studies in small animals, and an examples is the prototype of 
microSPET used in this project, that will be briefly explained follow. 
4.1. Hi-Cam: a new prototype of microSPET  
Hi-Cam prototype is a high resolution, small Field Of View (FOV), compact gamma 
ray imager, based on the Anger camera principle. Thanks to its characteristics, the 
potential applications of the imager in human medicine are in the field of intra 
operative probes and of cancer diagnosis, staging and therapy control. Moreover, 
the probe could be useful in pre-clinical validation of new drugs carried out with in 
vivo studies on small animals. The most relevant and innovative characteristic of 
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the Hi-Cam imager is the use of a non-standard silicon photo-detector for 
scintillation light readout. This detector is the Silicon Drift Detector, or SDD, which 
is characterized by a very low electronic noise, reached without any internal charge 
multiplication mechanism. Moreover, custom anti reflective coatings have been 
implemented on the entrance window of the detector, in order increase the 
Quantum Efficiency (QE). Thanks to these characteristics, the statistical and noise 
contributions to the energy resolution in gamma ray spectroscopy are reduced, 
eventually yielding to an improved image quality.  
The Hi-Cam imaging instrument is composed, starting from top, by a collimator, a 
single scintillator crystal, which covers all the units of the array of photo-detectors 
and converts the high energy γ-photons into many visible ones, and the photo-
detector array, which converts the light into electric signals. 
The position of interaction of the gamma photons inside the crystal is obtained by 
the scintillation light distribution among the elements of the array. The signals of 
the photo detectors are amplified and filtered by a multi-channel analog readout 
electronics and then sent to an acquisition board, where they are converted to 
digital values and sent to a PC. Finally, on the PC, a digital algorithm reconstructs 
the position of interaction of the photons in the crystal.  
The scintillator is made of CsI:Tl, which has a high light output, but a long decay 
time constant. The results confirm good performances, such as an energy 
resolution of 5.38 % on the 57Co peak, indicating that the SDD is an almost 
noiseless detector in the measured energy range, between 50 KeV and 700 KeV.  
The readout electronics is designed specifically for the Hi-Cam project and is 
composed of ten, 8-channel ASICs (Application Specific Integrated Circuits). Every 
single channel features a low noise preamplifier, a 6th order semi-gaussian shaping 
amplifier with selectable gain and peaking times in the µs range, a peak stretcher 
and a baseline holder. The 8-channel chip also features an analog multiplexer, 
registers for threshold programming, and some logic necessary for the multiplexer 
to work and for interfacing with the rest of the system. The acquisition system 
converts the peak values of the semi-gaussian shaping amplifiers, shifted out from 
the multiplexer, with a precision of 13 bits. The converted data are then stored in a 
FIFO memory for buffering and sent to the host PC, through a high-speed USB 
interface. Both the control of the acquisition board and the digital processing of the 
data, for calculating the position of interaction of the gamma photon inside the 
crystal basing on the Anger logic, is done on the PC. 
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